{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT ID: ['NCT04549064']\n",
      "Phase: []\n",
      "Start Date: ['September 1, 2020']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Biomarkers of Pancreatic Cancer and New Way to Detection']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nThe healthy control group had no history of benign pancreatic diseases and other benign and malignant tumors.\\nPatients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.\\n\\nExclusion Criteria:\\n\\nUncontrolled active infection.\\nAcute or chronic pancreatitis.\\nIt is accompanied by other uncontrolled malignant tumors.\\nAny other uncontrolled active disease that prevents participation in the trial.\\nHaving a history of mental illness that is difficult to control.\\nIn the opinion of the investigator, the presence of medical or psychiatric history or laboratory abnormalities may increase the risk associated with participation in the study or the administration of the study drug, or may interfere with the interpretation of the results.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05006131']\n",
      "Phase: []\n",
      "Start Date: ['July 10, 2020']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer, Adult']\n",
      "Brief Title: ['Pancreatic Cancer Screening for At-risk Individuals']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nInclusion criteria 1-3 are indications for pancreatic cancer screening as defined by the CAPS3 guidelines or updated national pancreatic cancer screening guidelines. Patients who do not meet these guidelines but are undergoing pancreatic cancer screening at the discretion of their treating physician at participating study centers will also be included in the study. Based upon the indication for screening, patients will be categorized as either meeting CAPS3 screening criteria, or not meeting CAPS3 screening criteria.\\n\\nFamilial Pancreatic cancer kindred. This is defined as family history of pancreas cancer that meet the criteria listed below.\\n\\nIf at least two affected relatives who are First degree relatives (FDR) to each other, of whom at least one is an FDR to the individual considered for surveillance\\nIf at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance\\nIf at least two affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance Screening is usually initialed at age 50 years or 10 years younger than the youngest family member with pancreatic cancer\\n\\nPatients with genetic susceptibility to pancreas cancer\\n\\nPatients with Peutz-Jeghers syndrome diagnosed with using clinical criteria or with a deleterious mutation in liver kinase B1/Serine/threonine kinase 11 (LKB1/STK11). Screening is usually initiated at age 40 years or later.\\nPatients with Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM syndrome), diagnosed using clinical criteria or CDKN2A p16 mutation.\\n\\nScreening is usually initiated at age 45 years or 10 years younger than the youngest family member with pancreatic cancer.\\n\\nHereditary Breast and Ovarian Cancer syndrome: diagnosed using clinical criteria or deleterious Breast Cancer gene 1 (BRCA1), Breast Cancer gene 2 (BRCA2), Partner and Localizer of BRCA2 (PALB2). The usual indication for screening is:\\n\\nBRCA1 mutation and at least one affected first-degree relative with pancreatic cancer\\nBRCA 2 mutation and at least one affected first-degree relative, or at least two relatives of any degree with pancreatic cancer\\nPALB2 mutation and at least one affected first-degree relative with pancreatic cancer Screening is usually initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer; or per updated national screening guidelines\\n\\nLynch syndrome or Ataxia Telangiectasia Mutated (ATM) mutations with at least one affected first-degree relative (FDR). Lynch syndrome could be diagnosed either by using clinical criteria or Mutator L homolog 1 (MLH1), Mutator S homolog 2 (MSH2), Mutator S homolog 6 (MSH6), Postmeiotic Segregation Increased, S. Cerevisiae, 2 (PMS2) or EPCAM mutation.\\n\\nScreening to be initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer.\\n\\nPatients with hereditary pancreatitis diagnosed using clinical criteria or deleterious Serine Protease 1 (PRSS1) mutation. Screening is usually initiated at age 40 years or 10 years younger than the youngest family member with pancreatic cancer 3. New-onset diabetes, age > 50 years with weight loss. 4. Patients who do not meet these CAPS screening criteria but are determined by the site principal investigator to be high-risk for pancreatic cancer based upon family history or other risk factors, and are undergoing pancreatic cancer screening will also be included in the study. Indication for pancreatic cancer screening and age at which screening was initiated will be recorded.\\n\\nExclusion Criteria:\\n\\nPatients presenting with symptoms suggestive of pancreatic cancer who are undergoing diagnostic EUS or MRCP e.g. acute recurrent pancreatitis, abnormal imaging']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05519930']\n",
      "Phase: []\n",
      "Start Date: ['October 18, 2016']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Pancreatic Cancer Early Detection Registry']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nEligible subjects must be ≥ 18 years of age\\n\\nMeet one of the following criteria:\\n\\nAll affected on the same side of the family (maternal/paternal) unless otherwise specified FDR = first degree relative (parent, sibling, child)\\nSDR = second degree relative (e.g., aunt, uncle, grandparent, half-sibling, niece and nephew)\\n\\nTDR = third degree relative (e.g., cousin, half-aunt or half-uncle)\\n\\n1 FDR with pancreatic cancer < age 55\\n\\n-≥2 FDR, SDR or TDR with pancreatic cancer at any age\\n\\nGenetic syndrome with pancreatic cancer\\nFDR or SDR with pancreatic cancer at any age and Ashkenazi ancestry\\n\\nFDR or SDR with pancreatic cancer at any age and:\\n\\n1 relative with ovarian cancer at any age or\\n1 relative with breast cancer ≤50 or\\n2 relatives with breast, pancreatic or prostate cancer (Gleason score ≥7) at any age\\nFamily history of melanoma OR\\nHas previously had genetic testing and has been determined to have a pathogenic gene variant.\\nFDR with a pathogenic gene variant\\n\\nExclusion Criteria:\\n\\nPrior treatment of pancreatic cancer including radiation therapy, systemic therapy and/or surgery.\\nCurrent treatment of pancreatic cancer including radiation therapy, systemic therapy and/or surgery.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00897832']\n",
      "Phase: []\n",
      "Start Date: ['January 2007']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion criteria\\n\\nDiagnosis of pancreatic cancer\\nExcess tissue collected at the time of routine surgery for pancreatic cancer must be available for analysis\\n\\nExclusion criteria\\n\\nNone known']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05188573']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['June 1, 2022']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\n≥50 years of age or older at the time of enrollment\\nWilling to provide and sign the informed consent form\\nMust have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):\\nFBG ≥126mg/dl\\nHbA1c ≥ 6.5%\\nRBG ≥200mg/dl\\n2-hour post-glucose ≥ 200mg/dl (OGTT)\\nMust have had glycemic parameter measured in 3-18 months prior to screening without meeting DM criteria\\nMust be willing to provide several tubes of blood without endangering health\\nNo history of pancreatic cancer\\nNo history of IPMNs, other neoplastic cysts and pancreatitis\\nNo active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated > 1 year prior to enrollment and in situ carcinomas)\\n\\nExclusion Criteria:\\n\\nPrior DM diagnosis\\nMet criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)\\nCarried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment\\nAny known pancreatic lesions\\nReceived cancer treatment within the past 5 years (with the exception of treatment of non- melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.\\nCurrent chronic or acute oral steroid use\\nHistory of intra-articular steroid injections (<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)\\nAny surgery requiring general anesthesia within 2 months of collection\\nLocal anesthetic (including dental novocaine) within 1 week of collection\\nHistory or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)\\nBlood transfusion within 1 month\\nOrgan transplant recipient\\nCurrently pregnant, or pregnancy within last 12 months\\nReceipt of systemic immunomodulation therapy within past 12 months\\nSignificant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00900003']\n",
      "Phase: []\n",
      "Start Date: ['May 2007']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Studying Biomarkers in Patients With Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion criteria\\n\\nAny subject with excess tissue collected at time of routine surgery for pancreatic cancer is eligible.\\nAll subjects participating in this protocol will be followed for recurrence, relapse and death from disease']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02581501']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['February 2016']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nHistologically confirmed adenocarcinoma of pancreas metastatic to any distant site. (Stage IV).\\nMust have a lesion reproducibly measurable by CT or MRI scans per Recist 1.1 criteria\\n\\nPrior radiation and surgery allowed (except Target lesions) but GAX treatment should be: >3 weeks since major surgery\\n\\nBilirubin < 1.5 mg/dL\\nPatients must have adequate liver function: AST and ALT < 2.5 X upper limit of normal, alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis is present (<5 X upper limit of normal) in the absence of liver metastasis.\\nPatients must have adequate bone marrow function: Platelets >100,000, Hemoglobin > 9.0g/dL and ANC > 1,500\\nPatients must have adequate renal function: creatinine <1.5 mg/dL is recommended\\nWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment.\\nPatients must have < Grade 2 pre-existing peripheral neuropathy (per CTCAE)\\nClinical Parameters Life expectancy > three months Age ≥ 18 years and ≤ 75 years Performance status 0-1 (ECOG) Pre-existing Peripheral Neuropathy (sensory) must be ˂ grade 2 Able to tolerate oral medications\\nInformed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.\\nPT/PTT within normal or therapeutic limits as determined by the investigator. All subjects will be on Xeloda, use of warfarin is exclusionary.\\n\\nExclusion Criteria:\\n\\nNeuroendocrine cancer should be ruled out by histology or immunohistochemical staining of the specimen. Mixed histology, pancreatic neuroendocrine and adenocarcinoma tumors, will also be excluded.\\nPrior chemotherapy is allowed, as long as less than or equal to two of the components of GAX were used previously for their treatment: this includes gemcitabine, capecitabine, 5-FU, or ABRAXANE® .\\nHypersensitivity: Patients with a history of severe hypersensitivity reaction to taxanes or other drugs formulated with polysorbate 80, or any of the other drugs in the GAX regimen are excluded.\\nSerious medical or psychiatric illness preventing informed consent or intensive treatment (e.g. serious infection) that would in the opinion of the investigator, increase the risk of serious neutropenic complications.\\nSerious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity.\\nPatients with compromised immune systems who are at increased risk of toxicity and lethal infections when treated with marrow-suppressive therapy.\\nSerious cardiovascular thromboembolic disease, including: congestive heart failure NYHA class III or greater; unstable angina or new onset angina (starting within three months of screening for this protocol), or myocardial infarction within the past 3 months (prior to screening); serious cardiac arrhythmias requiring therapy; cerebrovascular accident including transient ischemic attacks within the past 3 months (prior to screening).\\nSerious non-healing wound, ulcer, or bone fracture.\\nEvidence or history of bleeding diathesis.\\nMajor surgery, open biopsy or significant traumatic injury within 3 weeks of receiving first study drug.\\nUse of cytochrome P450 enzyme inducing drugs such as: antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital, but not Keppra), or St. John's Wort or rifampin (rifampicin).\\n\\nPrior malignancy in last 2 years other than curatively treated carcinoma in-situ of any site, non-melanoma skin cancer, or Stage I breast and/or bladder cancers (in situ), or early stage prostate cancer Stage I or II, curatively treated by surgery and/or radiation.\\n\\n-\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00727441']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['July 2, 2008']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery']\n",
      "EligibilityCriteria: ['DISEASE CHARACTERISTICS:\\n\\nNewly diagnosed adenocarcinoma of the head, neck, or uncinate process of the pancreas\\n\\nStage I or II disease\\n\\nSurgically resectable disease (R0 or R1) by spiral CT scan\\n\\nNo distant metastases\\nA clear fat plane is present around the celiac and superior mesenteric arteries\\nPatent superior mesenteric and portal veins\\nCandidate for a pancreaticoduodenectomy\\n\\nPATIENT CHARACTERISTICS:\\n\\nECOG performance status 0-1\\nHemoglobin ≥ 9 g/dL\\nANC ≥ 1,500/mm³\\nPlatelet count ≥ 100,000/mm³\\nSerum creatinine ≤ 2 mg/dL\\nAST and ALT ≤ 2 times upper limit of normal (ULN)\\nAmylase ≤ 2 times ULN\\nAlkaline phosphatase ≤ 5 times ULN\\nHyperbilirubinemia secondary to tumor-associated extrahepatic biliary obstruction allowed\\nNot pregnant or nursing\\nNegative pregnancy test\\nFertile patients must use effective contraception during and for ≥ 4 weeks after the completion of study treatment\\nNo history of autoimmune disease, including systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis\\nNo uncontrolled medical problems\\nNo active infections\\nNo other cancer within the past 5 years except for superficial bladder cancer, nonmelanoma skin cancer, or low-grade prostate cancer not requiring therapy\\n\\nPRIOR CONCURRENT THERAPY:\\n\\nMore than 28 days since prior anticancer therapy\\nNo prior cancer immunotherapy, including the same pancreatic cancer vaccine used in this study\\nMore than 28 days since prior systemic steroid therapy or immunosuppressive therapy\\nNo systemic steroid therapy or immunosuppressive therapy during and within 28 days after vaccine administration\\nNo other concurrent immunotherapy, chemotherapy, radiotherapy, gene therapy, biologic therapy, or investigational therapy for the treatment of pancreatic cancer']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05275075']\n",
      "Phase: []\n",
      "Start Date: ['December 7, 2022']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Resectable Pancreatic Adenocarcinoma']\n",
      "Brief Title: ['Identify microRNAs in Cachexia in Pancreatic Carcinoma']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nMale or female patient, who is ≥ 18 years old at the time of informed consent.\\nPatients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.\\nPatient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.\\nAbility to provide written informed consent and HIPAA authorization.\\n\\nExclusion Criteria:\\n\\nPatients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.\\nPatient has cancer diagnosis other than primary pancreatic adenocarcinoma.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT06043921']\n",
      "Phase: []\n",
      "Start Date: ['November 1, 2022']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nA. Unresectable Pancreatic Cancer:\\n\\nAt least 20 years of age at the time of consent\\n\\nHistopathologically confirmed adenocarcinoma and diagnosed as having ① or ② described below within 60 days prior to enrollment\\n\\nClinical Stage Ⅲ (T1-3N2M0, T4 anyNM0)\\n\\nClinical Stage Ⅳ (anyTanyNM1)\\nScheduled to receive systemic chemotherapy for unresectable pancreatic cancer.\\nNo prior treatment for pancreatic cancer\\nWilling to provide blood and tissue samples in accordance with the research protocol.\\nAdequate tissue samples are available\\nWritten informed consent for participating in this study\\n\\nB. Resectable Pancreatic Cancer:\\n\\nAt least 20 years of age at the time of consent.\\nTissue sample collected by EUS-FNA/FNB and histopathologically diagnosed as having adenocarcinoma.\\n\\nDiagnosed as having cancer meet any one of a to d below within 60 days prior to enrollment\\n\\ncStage IA (T1 N0 M0)\\ncStage IB (T2 N0 M0)\\ncStage IIA (T3 N0 M0)\\ncStage IIB (T1-3 N1 M0)\\nScheduled to undergo surgery for resectable pancreatic cancer.\\nNo history of prior treatment for pancreatic cancer.\\nWilling to submit blood and tissue samples in accordance with the research protocol.\\nAdequate tissue samples are available\\nWritten informed consent for participating in this study\\n\\nExclusion Criteria:\\n\\nCommon exclusion criteria for both the unresectable and resectable pancreatic cancer patient cohorts:\\n\\nSynchronous double/multiple cancer or metachronous double/multiple cancer with progression free period of 2 years or shorter.\\nWomen who are pregnant or planning to become pregnant.\\nJudged by the investigator as being unsuitable for participation in the study.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00569387']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['December 2007']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Vaccine Study for Surgically Resected Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nA histological diagnosis of adenocarcinoma of the pancreas.\\nAJCC Stage I or II Pancreatic carcinoma (See Appendix A). Patients must have undergone surgical resection for the tumor and extent of resection must be either R0 (complete resection with grossly and microscopically negative margins of resection) or R1 (grossly negative but positive microscopically margins of resection).\\nEastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.\\nSerum albumin ≥ 2.0 gm/dL.\\nExpected survival ≥ 6 months.\\nSubjects must have a negative serology for HIV prior to entering study.\\nSubjects must be able to take in ≥ 1500 calories daily.\\nAdequate organ function including:\\nMarrow: WBC ≥3000/mm3 and platelets ≥100,000/mm3.\\nHepatic: serum total bilirubin ≤ 2 x ULN mg/dL, ALT (SGPT) and AST (SGOT) ≤3 x upper limit of normal (ULN).\\nRenal: serum creatinine (sCr) ≤2.0 x ULN, or creatinine clearance (Ccr) ≥30 mL/min.\\nFirst vaccination must be within 6 weeks after surgery.\\nPatients must have the ability to understand the study, its inherent risks, side effects and potential benefits and be able give written informed consent to participate.\\nAll subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product, and for one month after the last immunization.\\n\\nExclusion Criteria:\\n\\nAge <18-years-old.\\nActive metastases.\\nOther malignancy within five years, unless the probability of recurrence of the prior malignancy is <5%. Patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.\\nHistory of organ transplant.\\nCurrent, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.\\nSubjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics, not to exceed 10 mg Decadron weekly. Subjects may also receive pulse doses for Gemcitabine hypersensitivity, not to exceed Decadron 8 mg BID x 3 days prior to start day of Gemcitabine. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning vaccination, will be removed from study.\\nSignificant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.\\nActive infection or antibiotics within 1-week prior to study, including unexplained fever (temp > 38.1C).\\nAutoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), etc.). Patients with a remote history of asthma or mild active asthma are eligible.\\nOther serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., liver cirrhosis) or a serious illness in medical opinion of the clinical investigator.\\nAny condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.).\\nA known allergy to any component of the vaccine or cell lines.\\nPregnant or nursing women due to the unknown effects of vaccination on the developing fetus or newborn infant. (For patients with child bearing potential, a βHCG must be completed within 7 days of first vaccination).\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03250078']\n",
      "Phase: []\n",
      "Start Date: ['November 2016']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Neoplasms']\n",
      "Brief Title: ['A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals']\n",
      "EligibilityCriteria: ['Registration-Inclusion Criteria for FAMILIAL PANCREATIC CANCER (FPC) and those with a BRCA1, BRCA2, LYNCH SYNDROME, ATM, PALB2, CDKN2A, or related gene mutation (one of the following is required for questions 1-3)\\n\\nFor FPC: The individual has at least 2 first-degree relatives (FDR) with PC.\\nFor FPC: The individual has at least 3 first-, second-, or third-degree relatives with PC with at least 1 PC in a FDR.\\nThe individual is a known mutation carrier of BRCA1, BRCA2, MLH1, MSH2, MSH6, or PMS2, ATM, PALB2, CDKN2A, or similar high-risk gene mutation and has at least 1 first- or second-degree relative with PC.\\nThe individual is at least 50 years old or 10 years younger than the youngest relative with PC.\\nFamily and genetic history confirmed by genetics counselor at WCHN.\\nECOG Performance Status of 0-1.\\nNo known contraindications to MRI examination or gadolinium contrast.\\nWilling to undergo MRI and screening for metal implants or metal injury.\\nPrior BUN and Cr\\nEstimated GFR (eGFR) must be greater than 30 mL/min.\\nAbility to provide informed consent.\\nWilling to return to study site for all study assessments.\\n\\nRegistration-Exclusion Criteria:\\n\\nPrior history of pancreatic cancer.\\nPresence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.\\nReceived chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).\\nHereditary pancreatitis.\\neGFR < 30 mL/min\\nContraindication to MRI examination or gadolinium contrast.\\nPregnant or nursing women.\\nCo-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00614601']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['January 2008']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nA histological diagnosis of adenocarcinoma of the pancreas. The patient's pathology must be reviewed and confirmed by the clinical site's Pathology Department.\\nAJCC Stage I or II Pancreatic carcinoma. Patients must have undergone surgical resection for the tumor and extent of resection must be either R0 (complete resection with grossly and microscopically negative margins or resection) or R1 (grossly negative but positive microscopically margins of resection).\\nEastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.\\nSerum albumin ≥ 2.0 gm/dL.\\nExpected survival ≥ 6 months.\\nSubjects must have a negative serology for HIV prior to entering study.\\nSubjects must be able to take in ≥ 1500 calories daily.\\nAdequate organ function including:\\nMarrow: WBC ≥3000/mm3 and platelets ≥100,000/mm3.\\nHepatic: serum total bilirubin ≤ 2 x ULN mg/dL, ALT (SGPT) and AST (SGOT) ≤3 x upper limit of normal (ULN).\\nRenal: serum creatinine (sCr) ≤2.0 x ULN, or creatinine clearance (Ccr) ≥30 mL/min.\\nFirst vaccination must be within 6 weeks after surgery.\\nPatients must have the ability to understand the study, its inherent risks, side effects and potential benefits and be able give written informed consent to participate.\\nAll subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product, and for one month after the last immunization.\\n\\nExclusion Criteria:\\n\\nAge <18-years-old.\\nActive metastases.\\nOther malignancy within five years, unless the probability of recurrence of the prior malignancy is <5%. Patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.\\nHistory of organ transplant.\\nCurrent, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.\\nSubjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics, not to exceed 10 mg Decadron weekly. Subjects may also receive pulse doses for Gemcitabine hypersensitivity, not to exceed Decadron 8 mg BID x 3 days prior to start day of Gemcitabine. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning vaccination, will be removed from study.\\nSignificant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.\\nActive infection or antibiotics within 1-week prior to study, including unexplained fever (temp > 38.1C).\\nAutoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), etc.). Patients with a remote history of asthma or mild active asthma are eligible.\\nOther serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., liver cirrhosis) or a serious illness in medical opinion of the clinical investigator.\\nAny condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.).\\nA known allergy to any component of the vaccine or cell lines.\\nPregnant or nursing women due to the unknown effects of vaccination on the developing fetus or newborn infant. (For patients with child bearing potential, a βHCG must be completed within 7 days of first vaccination).\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05596435']\n",
      "Phase: []\n",
      "Start Date: ['October 10, 2022']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Early Detection of Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nAge minimum 18 years\\nParticipants must have histologically and/or cytologically confirmed stage I/II/III pancreatic cancer\\nFull access to the patients' clinical and pathological records\\nAbility to understand and the willingness to sign a written informed consent document\\nNon-cancer controls are sex- and age-matched individuals without presence of any tumors or nodules or any other severe chronic diseases through systematic screening\\n\\nExclusion Criteria:\\n\\nParticipants must not be pregnant or breastfeeding\\nParticipants must not have prior cancer histories or a second non-pancreatic malignancy\\nParticipants must not have had any form of cancer treatment before enrollment or plasma collection, including surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy\\nParticipants must not present medical conditions of fever or have acute or immunological diseases that required treatment 14 days before plasma collection\\nParticipants who underwent organ transplant or allogenic bone marrow or hematopoietic stem cell transplantation\\nParticipants with clinically important abnormalities or conditions unsuitable for blood collection\\nAny uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction, major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or psychiatric illness/social situations that would limit compliance with study requirements or influence patient signing the written informed consent\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03544255']\n",
      "Phase: []\n",
      "Start Date: ['May 1, 2018']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer', 'Pancreas Adenocarcinoma']\n",
      "Brief Title: ['Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\n1) Patients suspected to have pancreatic cancer who will receive EUS-FNA for diagnosis; 2) Patients who have signed the informed consent.\\n\\nExclusion Criteria:\\n\\n1) Those who are under the age of 18; 2) Patients who have received adjuvant chemoradiotherapies or other anti-tumor therapies; 3) Patients with critical illness and cannot tolerate the operations; 4) Women who have been pregnant or are planning to be pregnant.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05327400']\n",
      "Phase: []\n",
      "Start Date: ['May 1, 2022']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Gene Expression']\n",
      "Brief Title: ['Expression and Clinical Significance of IGHD in Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients with pathologically confirmed pancreatic cancer\\n\\nExclusion Criteria:\\n\\nnoperable patients\\nother malignant tumors']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02934984']\n",
      "Phase: []\n",
      "Start Date: ['July 2016']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nComparative group : Pancreatic cancer patients who progress endoscopic ultrasonography fine-needle aspiration (EUS-FNA) for pancreatic cancer diagnosis, pancreatic cancer patients who are in operable stage\\nControl group : Benign pancreas disease patients who progress EUS-FNA for diagnosis, healthy population\\n\\nExclusion Criteria:\\n\\nForeigners\\nPancreatic cancer patients who have other cancer\\nPatients who impossible to consent to study by own']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02449967']\n",
      "Phase: ['Phase 1', 'Phase 2']\n",
      "Start Date: ['May 2015']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nAge:18-80\\nKarnofsky performance status >60\\nDiagnosis of pancreatic cancer based on histology or the current accepted radiological measures.\\nClassification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ\\nWill receive interventional therapy\\nLife expectancy: Greater than 3 months\\nPatients' routine blood test, liver function and kidney function have no obvious abnormalities\\nAbility to understand the study protocol and a willingness to sign a written informed consent document\\n\\nExclusion Criteria:\\n\\nPatients with other primary tumor except pancreatic cancer\\nHistory of coagulation disorders or anemia\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00994721']\n",
      "Phase: []\n",
      "Start Date: ['February 2009']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['A Phase III Study of Pancreatic Cancer']\n",
      "EligibilityCriteria: ['A.Eligibility Criteria\\n\\nPatients with pancreatic cancer after curative intent resection.\\nThe histology of resected tumor has to be adenocarcinoma.\\nAge 20-75 years.\\nECOG performance scale 0-1.\\nPatients must have normal organ and marrow function as defined below.\\nThe effects of study agents on the developing human fetus at the recommended therapeutic dose are unknown.\\nto sign a written informed consent.\\nRegistered within 6 weeks after surgery.\\nPreoperative abdominal CT or MRI with contrast enhancement.\\n\\nB.Exclusion Criteria\\n\\nPatients with gross residual, macroscopic positive resection margin or distant metastases.\\nPatients may not be receiving any other investigational agents.\\nPatients who have had prior chemotherapy or radiotherapy are not eligible.\\nHistory of allergic reactions.\\nPatients who had non-curable second primary malignancy.\\nUncontrolled intercurrent illness including.\\nPregnant women.\\nreceiving immuno-suppressive therapy、anti-coagulants.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03937453']\n",
      "Phase: []\n",
      "Start Date: ['January 19, 2018']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer', 'Pancreatic Neoplasms']\n",
      "Brief Title: ['A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAge of at least 50 years.\\nDM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR\\nDM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR\\nTransition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR\\nDM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR\\nDeteriorating Diabetes: DM with >2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance\\nECOG Performance Status of 0-1.\\nNo known contraindications to MRI examination or gadolinium contrast.\\nWilling to undergo MRI and screening for metal implants or metal injury.\\nRecent BUN and Cr\\nEstimated GFR (eGFR) must be greater than 30 mL/min.\\nAbility to provide informed consent.\\nWilling to return to study site for all study assessments.\\n\\nExclusion Criteria:\\n\\nPrior history of pancreatic cancer.\\nPresence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.\\nReceived chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).\\nHereditary pancreatitis.\\neGFR < 30 mL/min.\\nContraindication to MRI examination or gadolinium contrast.\\nPregnant or nursing women.\\nCo-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01102569']\n",
      "Phase: []\n",
      "Start Date: ['January 2008']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Pancreatic Cancer Genetics']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients diagnosed with pancreatic cancer.\\nPatients are of Ashkenazi Jewish descent.\\nPatients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154).\\n\\nExclusion Criteria:\\n\\nInability to provide informed consent.\\nUnder the age of 18 years old.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00836407']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['February 2009']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nDocumented cancer of the pancreas who have failed (or are not candidates for) standard therapy\\nECOG Performance Status of 0 to 1\\nAdequate organ function as defined by study-specified laboratory tests\\nMust use acceptable form of birth control through the study and for 28 days after final dose of study drug\\nSigned informed consent form\\nWilling and able to comply with study procedures\\n\\nExclusion Criteria:\\n\\nCurrently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions\\nClinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0\\nSystemically active steroids\\nAnother investigational product within 28 days prior to receiving study drug\\nMajor surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug\\nInfection with HIV, hepatitis B or C at screening\\nPregnant or lactating\\nConditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00885248']\n",
      "Phase: []\n",
      "Start Date: ['January 2009']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPancreatic mass suspicious of pancreatic cancer\\nNo comorbidity, expected life expectancy less than 6 months\\nConsent this study in letter\\n\\nExclusion Criteria:\\n\\nRefuse diagnostic and staging work-up']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04466189']\n",
      "Phase: []\n",
      "Start Date: ['September 21, 2018']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreas Cancer']\n",
      "Brief Title: ['Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPancreatic cancer patients scheduled to be proton beam therapy\\nAgreed to participate in this study\\n\\nExclusion Criteria:\\n\\n-Disagreed to participate in this study']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05188586']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['December 6, 2022']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\n≥ 50 years of age or older at the time of enrollment\\n\\nWilling to sign the informed consent form\\n\\nMust have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):\\n\\nFBG ≥126mg/dl HbA1c ≥6.5% RBG ≥ 200mg/dl 2-hour post-glucose ≥200mg/dl (OGTT)\\n\\nMust have had glycemic parameter measured in 3-18 months prior to screening that did NOT meet DM criteria\\n\\nMust be willing to provide several tubes of blood without endangering health\\n\\nNo history of pancreatic cancer or other known pancreatic neoplasia\\n\\nNo active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated > 1 year prior to enrollment and in situ cancers)\\n\\nExclusion Criteria:\\n\\nPrior DM diagnosis\\n\\nMet criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)\\n\\nCarried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment\\n\\nAny known pancreatic lesions (aside from diabetes)\\n\\nReceived cancer treatment within the past 5 years (with the exception of treatment of non-melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.\\n\\nCurrent chronic or acute oral steroid use\\n\\nHistory of intra-articular steroid injections (<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)\\n\\nAny surgery requiring general anesthesia within 2 months of collection\\n\\nLocal anesthetic (including dental novocaine) within 1 week of collection\\n\\nHistory or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)\\n\\nBlood transfusion within 1 month\\n\\nOrgan transplant recipient\\n\\nCurrently pregnant, or pregnancy within last 12 months\\n\\nReceipt of systemic immunomodulation therapy within past 12 months\\n\\nSignificant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01272791']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['January 2011']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nWritten informed consent has been obtained.\\nAdults of 18 years of age or older with a life expectancy of at least 3 months.\\nPatients with histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas.\\nEastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\\nAdequate hematologic function (ANC ≥ 1,500 cells/µL; hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL).\\nAdequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min).\\nAdequate hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN); ALT and AST may be <5 x ULN if due to liver metastases.\\nPT/INR ≤ 1.5 × ULN.\\naPTT ≤ 1.5 × ULN.\\nFemale patients must have a negative urine or serum pregnancy test at screening (pregnancy test not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are > 1 year postmenopausal).\\nAll patients of reproductive potential must agree to use an approved form of contraception (as determined by the investigator).\\n\\nExclusion Criteria:\\n\\nNeuroendocrine tumors (carcinoid, islet cell cancer) of the pancreas.\\nNYHA Class III or IV, cardiac function, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease.\\nKnown brain, leptomeningeal or epidural metastases.\\nRadiation therapy within 7 days of Study Day 1, lack of recovery from previous therapeutic radiation, or planned radiation therapy during the study period.\\nPreviously received any systemic treatment for pancreatic cancer, including prior neoadjuvant or adjuvant chemotherapy for lower stage disease.\\nPreviously malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years.\\nSevere chronic obstructive or other pulmonary disease with hypoxemia.\\nMajor surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery.\\nActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.\\nOngoing therapy with oral or parenteral anticoagulants; patients on low-dose anticoagulants to maintain patency of lines are eligible.\\nVenous thromboembolic events (e.g. deep vein thrombosis or pulmonary embolism) within 6 months of screening.\\nQTC interval of >470 ms on screening.\\nLong QT syndrome or family history of sudden cardiac death in young family members.\\nSubjects who participated in an investigational drug or device study within 28 days prior to study entry.\\nKnown active infection with HIV, hepatitis B, or hepatitis C.\\nFemales who are pregnant or breast-feeding.\\nConcomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.\\nUnwillingness or inability to comply with the study protocol for any reason.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00409292']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['January 2007']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPathologic confirmation of pancreatic adenocarcinoma\\n18 years of age or older\\nAt least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.\\nTreated with gemcitabine-based chemotherapy with documented tumor progression on gemcitabine or intolerance to gemcitabine.\\nPrior treatment with no more than 1 prior chemotherapy regimen for metastatic disease.\\nMinimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anti-cancer therapy.\\nECOG performance status 0-1.\\nLife expectancy of greater than 12 weeks.\\nAdequate bone marrow and liver function.\\nMust be able to swallow tablets.\\n\\nExclusion Criteria:\\n\\nPrior treatment with an investigational drug within the preceding 4 weeks.\\nPrior treatment with an inhibitor of mTOR\\nChronic treatment with systemic steroids or another immunosuppressive agent\\nMore than one prior chemotherapy treatment for metastatic disease\\nUncontrolled brain or leptomeningeal metastases, including patient who continue to require glucocorticoids for brain or leptomeningeal metastases.\\nOther malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin\\nPatients with chronic renal insufficiency\\nOther concurrent severe and/or uncontrolled medical disease which could compromise participation in the study.\\nKnown history of HIV seropositivity\\nImpairment of gastrointestinal function or gastrointestinal disease that my significantly alter the absorption of RAD001.\\nActive, bleeding diathesis or an oral vitamin K antagonist medication\\nWomen who are pregnant or breast feeding']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03821909']\n",
      "Phase: []\n",
      "Start Date: ['August 1, 2018']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Acquisition of Portal Venous CTCs and Exosomes From Patients With Pancreatic Cancer by EUS']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAged from 18 to 80 years-old\\nSuspected pancreatic masses and referred for EUS-FNA for pathology diagnosis\\nWritten informed consent\\n\\nExclusion Criteria:\\n\\nPatients who have received adjuvant chemotherapy and other anti-tumor treatments\\nSevere heart, lung, liver, kidney insufficiency, or severe bleeding disorders, severe coagulopathy or local/systemic infections, other critical illnesses\\nWomen who are planning to become pregnant or are pregnant or breast-feeding']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03837132']\n",
      "Phase: []\n",
      "Start Date: ['October 15, 2018']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Advanced Cancer']\n",
      "Brief Title: ['Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nage >18\\nnewly diagnosed advanced pancreatic cancer (APC)\\nEnglish speaking or willing to be seen with a medical interpreter\\nwilling and able to complete quality of life (QoL) questionnaires\\n\\nExclusion Criteria:\\n\\nage <18\\nreceiving cycle 2 of chemotherapy']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04427761']\n",
      "Phase: []\n",
      "Start Date: ['June 5, 2020']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['A Study of the Life Changes Experienced by Patients With Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nadult patients 18 years of age and older\\nprimary language listed as English in electronic medical record\\nbiopsy proven diagnosis of pancreatic cancer\\nwithin three months after initiating a chemotherapy regimen at the Rockefeller Outpatient Pavilion at MSKCC (patient may have previously received chemotherapy at an outside institution or may have received previous chemotherapy regimens at MSKCC).\\n\\nExclusion Criteria:\\n\\nprevious history of cancer within the past five years, except for non-melanoma skin cancer, ductal carcinoma in situ breast cancer, and thyroid cancer.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03513705']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['May 22, 2018']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Carcinoma, Pancreatic Ductal']\n",
      "Brief Title: ['Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)']\n",
      "EligibilityCriteria: ['Inclusion Criteria patients:\\n\\nAll pancreatic cancer patients\\n\\nExclusion Criteria patients:\\n\\nThere are no specific exclusion criteria\\n\\nInclusion Criteria clusters:\\n\\nAll 17 centers of the DPCG. These centers each perform >20 pancreatoduodenectomies (PDs) annually. Each center already has a coordinating role for pancreatic cancer for its region. It is expected that the enhanced implementation of best practices will have an impact in the entire local network\\n\\nExclusion Criteria clusters:\\n\\nThere are no specific center exclusion criteria']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00084383']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['January 2002']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas']\n",
      "EligibilityCriteria: [\"DISEASE CHARACTERISTICS:\\n\\nHistologically confirmed invasive ductal adenocarcinoma of the head, neck, and uncinate process of the pancreas\\n\\nMixed adenocarcinoma tumors allowed if the predominant invasive component of the tumor is adenocarcinoma\\nStage I or II (clinical stage T1-3, N0-1, M0) disease\\n\\nHas undergone pancreaticoduodenectomy at the Johns Hopkins Hospital within the past 8-10 weeks\\n\\nCompletely resected (R0) or microscopic residual (R1) disease\\n\\nNo diagnosis other than ductal adenocarcinoma, including any of the following:\\n\\nAdenosquamous\\nSquamous cell\\nColloid\\nIslet cell\\nNon-invasive intraductal papillary mucinous neoplasms\\nSerous or mucinous cystadenoma or cystadenocarcinoma\\nCarcinoid\\nSmall or large cell carcinoma\\nIntraductal oncocytic papillary neoplasms\\nOsteoclast-like giant cell tumors\\nAcinar cell carcinoma\\nPancreatoblastoma\\nSolid pseudopapillary tumors\\nUndifferentiated small cell carcinoma\\nNon-epithelial tumors (sarcoma, gastrointestinal stromal tumor, or lymphoma)\\nAdenocarcinoma of the ampulla\\nAdenocarcinoma of the distal bile duct\\nAdenocarcinoma of the duodenum\\nNo recurrent disease\\nNo metastatic disease, including peritoneal implants or liver and/or lung involvement\\n\\nPATIENT CHARACTERISTICS:\\n\\nAge\\n\\n18 and over\\n\\nPerformance status\\n\\nECOG 0-1\\n\\nLife expectancy\\n\\nNot specified\\n\\nHematopoietic\\n\\nAbsolute neutrophil count >/= 1,500/mm^3\\nPlatelet count >/= 100,000/mm^3\\nHemoglobin >/= 10 g/dL\\n\\nHepatic\\n\\nBilirubin </= 2 mg/dL\\nAST/ALT </= 2 times upper limit of normal (ULN)\\nAlkaline phosphatase </= 5 times ULN\\n\\nRenal\\n\\nCreatinine </= 2 mg/dL\\n\\nPulmonary\\n\\nNo asthma or chronic obstructive pulmonary disease requiring systemic corticosteroids\\n\\nImmunologic\\n\\nHIV negative\\nNo active infection\\n\\nNo prior or concurrent autoimmune disease requiring treatment with systemic immunosuppressants, including any of the following:\\n\\nInflammatory bowel disease\\nSystemic vasculitis\\nScleroderma\\nPsoriasis\\nMultiple sclerosis\\nHemolytic anemia or immune thrombocytopenia\\nRheumatoid arthritis\\nSystemic lupus erythematosus\\nSjogren's syndrome\\nSarcoidosis\\nNegative results to viral delayed-type hypersensitivity serology testing if autologous tumor cells are available\\n\\nOther\\n\\nNo postoperative complications (e.g., inability to take oral nutrition >/= 1,500 calories/day, ongoing requirement for long-term biliary stenting, or persistence of wound infection)\\nNo other malignancy within the past 5 years except nonmelanoma skin cancer\\nNo uncontrolled medical conditions that would preclude study participation\\nNo other major active medical or psychosocial problem that could be exacerbated by study treatment\\nNot pregnant or nursing\\nNegative pregnancy test\\nFertile patients must use effective contraception during and for at least 4 weeks after study participation\\n\\nPRIOR CONCURRENT THERAPY:\\n\\nBiologic therapy\\n\\nMore than 1 month since prior biologic therapy\\nNo other concurrent biologic therapy, immunotherapy, or gene therapy for pancreatic cancer\\n\\nChemotherapy\\n\\nMore than 1 month since prior chemotherapy\\nNo other concurrent chemotherapy for pancreatic cancer\\n\\nEndocrine therapy\\n\\nMore than 28 days since prior systemic steroids\\nNo concurrent systemic corticosteroids\\n\\nRadiotherapy\\n\\nMore than 1 month since prior radiotherapy\\nNo other concurrent radiotherapy for pancreatic cancer\\n\\nSurgery\\n\\nSee Disease Characteristics\\nRecovered from prior surgery\\n\\nOther\\n\\nMore than 1 month since prior participation in an investigational new drug trial\\nNo other concurrent investigational therapy for pancreatic cancer\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02080221']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['August 2014']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPathologically or cytological confirmed pancreatic ductal adenocarcinoma. Patients with pathology or cytology showing carcinoma of pancreas or adenosquamous of the pancreas are also eligible.\\nMetastatic advanced disease.\\nNo prior chemotherapy for pancreatic cancer\\nNo major surgery within 3 weeks of the start of study treatment. Patients must have recovered from the side effects of any major surgery at the start of study treatment. For questions on if a surgery is deemed \"major,\" definition by surgeon can be used for clarification. Laparoscopy and central venous catheter placement are not considered major surgery.\\nNo prior invasive malignancy within the prior two years. However, patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer or asymptomatic prostate cancer) are eligible.\\nECOG performance status 0 or 1.\\nAge ≥ 18\\nNot pregnant and not nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment. Post-menopausal women (surgical menopause or lack of menses >12 months) do not need to have a pregnancy test, please document status.\\nWomen of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment. Documentation of this being discussed required.\\n\\nRequired Initial Laboratory Values:\\n\\nNeutrophils ≥ 1,500/mm3\\nPlatelet count ≥ 100,000/mm3\\nCreatinine ≤ 1.5 mg/dL -or- creatinine clearance ≥ 60 mL/min\\nTotal bilirubin ≤ 1.25 x ULN\\nAST (SGOT) & ALT (SGPT) ≤ 2.5 x ULN (for patients with liver metastases, AST&ALT < 5xULN)\\nAlkaline phosphatase < 2.5xULN, unless bone metastasis is present and in the absence of liver metastasis\\n\\nExclusion Criteria:\\n\\nPatients with known brain metastases\\nPrior hypersensitivity to Oxaliplatin or Abraxane ® that in the investigators opinion would put the patient at risk if re-exposed\\nPreexisting neuropathy\\nPatients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A 5. Patients with unstable biliary stents or with plastic stents. Information on type of stent is required at registration.\\n\\n6. Patients with active infection or fever (patients on antibiotics for infection or patients getting over a cold or seasonal virus are not excluded), or known historical or active infection with HIV, hepatitis B, or hepatitis C.\\n\\n7. Patients with sepsis or pneumonitis. 8. Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies that in the investigator\\'s opinion would put the patient at an increased risk.\\n\\n10. Uncontrolled diabetes. If patient has diabetes, confirmation on status (controlled or uncontrolled) required at registration.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01692873']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['February 2012']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Tumor']\n",
      "Brief Title: ['Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nSuspicion of pancreatic adenocarcinoma\\nPatient > 18 years old\\nSocial Security affiliation\\nSigned informed consent\\n\\nExclusion Criteria:\\n\\nPatient in emergency situation\\nMajor person being the object of a legal protective measure or unable to express its consent']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01104129']\n",
      "Phase: []\n",
      "Start Date: ['July 9, 2009']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Stool Testing for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\n18 years of age and older.\\nTissue-confirmed or radiological evidence of either pancreatic adenocarcinoma or intrapapillary mucinous neoplasm(IPMN).\\nScheduled for surgical resection of the adenocarcinoma or IPMN.\\nAble to give informed consent\\n\\nExclusion Criteria:\\n\\nHistory of colorectal, gastric cancer, esophageal, or head-and-neck cancer.\\nEndoscopic procedure conducted less than 1 week prior to enrollment.\\nUnwillingness or inability to sign informed consent.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01488552']\n",
      "Phase: ['Phase 1', 'Phase 2']\n",
      "Start Date: ['November 2011']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Stage IV Pancreatic Cancer']\n",
      "Brief Title: ['Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHistologically documented Stage IV metastatic adenocarcinoma of the pancreas with measurable disease\\nPerformance status ECOG 0 or 1\\nPatients may not have received prior treatment for metastatic pancreatic adenocarcinoma except for receiving gemcitabine or 5FU as a radiosensitizer along with radiation therapy; or have received gemcitabine for adjuvant treatment if they have been off gemcitabine for > 12 months\\nAdult (>18 years of age) male or non-pregnant and non-lactating female\\nA negative serum pregnancy test (Beta-hCG) documented within 72 hours of the first administration of study drug in female patients of child-bearing potential\\nAgreement to use contraception considered adequate and appropriate by the investigator\\n\\nThe following blood counts at baseline:\\n\\nANC >/= 1.5 x 109/L\\nHgb > 9g/dL\\nPlatelets >100 x 109/L\\n\\nThe following blood chemistry levels at baseline:\\n\\nAST and ALT </= 2.5 x upper limit of normal range (ULN) or < 5.0 ULN if liver metastasis are present\\nBilirubin </= ULN\\nSerum creatinine within 1.5 x ULN\\nPT, INR within 1.5 x ULN unless on therapeutic doses of warfarin\\nMust have measurable disease outside the pancreas by RECIST criteria\\nNo clinically significant abnormalities in urinalysis results\\nVoluntary agreement to participate in this study after being informed about the nature of the study including potential risks and benefits and having the ability to have questions addressed. The patient must sign and date the IRB approved Informed Consent Form (ICF) prior to participation in any study-related procedures\\n\\nExclusion Criteria:\\n\\nHas pancreatic islet cell neoplasms\\nIs pregnant or lactating\\nHas active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\\nKnown infection with HIV, Hepatitis B or Hepatitis C.\\nPatient with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies (see section 4.4.9)\\nHas a serious medical risk factor(s) involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.\\nIs unwilling or unable to comply with study procedures.\\nIs enrolled in any other investigational trial.\\n\\nCaution of observation for interstitial pneumonitis in patients prior to enrollment:\\n\\nBefore enrollment, evaluate candidate patients fro familial, environmental or occupational exposure to opportunistic pathogens, and do not enroll those with a history of slowly progressive dyspnea and unproductive cough, or of conditions such as sarcoidosis, silicosis. idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02162823']\n",
      "Phase: []\n",
      "Start Date: ['May 2007']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Clinical Trial of Pancreatic Cancer in Stockholm.']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\npancreatic cancer patients that aged less than 85 years old born in Sweden living in Stockholm\\nwritten informed consent\\n\\nExclusion Criteria:\\n\\npancreatic cancer older than 85 years\\npancratic cancer younger than 18 years\\nnot willing to participate']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02343835']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['January 1, 2015']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nRadiologic confirmation of unresectable pancreatic cancer by at least CT of chest and abdomen\\nScreening must be performed no longer than 2 weeks prior to study inclusion\\nMaximum tumor diameter ≤ 5 cm;\\nHistological or cytological confirmation of pancreatic adenocarcinoma;\\nAge ≥ 18 years;\\nASA-classification 0 - 3\\nLife expectancy of at least 12 weeks;\\n\\nAdequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to definite inclusion;\\n\\nHemoglobin ≥ 5.6 mmol/L;\\nAbsolute neutrophil count (ANC) ≥ 1,500/mm3;\\nPlatelet count ≥ 100*109/l;\\nTotal bilirubin ≤ 1.5 times the upper limit of normal (ULN);\\nALT and AST ≤ 2.5 x ULN;\\nSerum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 50 ml/min;\\nProthrombin time or INR < 1.5 x ULN;\\nActivated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed if this treatment can be interrupted as judged by the treating physician);\\nWritten informed consent;\\n\\nExclusion Criteria:\\n\\nResectable pancreatic adenocarcinoma as discussed by our multidisciplinary hepatobiliary team;\\nSuccessful down staging after (radio)chemotherapy from previous unresectable/borderline tumor to resectable tumor;\\nHistory of epilepsy;\\n\\nHistory of cardiac disease:\\n\\nCongestive heart failure >NYHA class 2;\\nActive Coronary Artery Disease (defined as myocardial infarction within 6 months prior to screening);\\nCardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted);\\nUncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;\\nCompromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites);\\nUncontrolled infections (> grade 2 NCI-CTC version 3.0);\\nPregnant. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment;\\nImmunotherapy ≤ 6 weeks prior to the procedure;\\nChemotherapy ≤ 6 weeks prior to the procedure;\\nRadiotherapy ≤ 6 weeks prior to the procedure;\\nConcomitant use of anti-convulsive and anti-arrhythmic drugs (other than beta blockers used for antihypertensive);\\nAllergy to contrast media;\\nAny implanted stimulation device;\\nAny implanted metal stent/device within the area of ablation that cannot be removed;\\nAny condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study; Of note, patients with contra-indications for MRI will not be excluded from participation: in this case radiologic follow-up will consist of CT-scanning according to protocol.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02358161']\n",
      "Phase: ['Phase 1', 'Phase 2']\n",
      "Start Date: ['September 2015']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nPatients must provide written informed consent according to International Conference on Harmonisation of technical requirements for registration og pharmaceuticals for human use (ICH)/Good cClinical Practice (GCP), and national/local regulations prior to any screening procedures.\\nMale or female adult patients (> 18 years)\\nPatients with histologically/cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma.\\n\\na. Phase I: patients with non resectable or metastasized pancreatic ductal adenocarcinoma.\\n\\nb. Phase II: patients with non resectable or metastasized pancreatic ductal adenocarcinoma not pre-treated with chemotherapy or radiotherapy, unless adjuvant treatment with gemcitabine > 6 months prior to inclusion.\\n\\nMeasurable disease as assessed by RECIST 1.1 (Response Evaluation Criteria In Solid Tumors) .\\nECOG (Eastern Cooperative Oncology Group) (WHO) performance status 0-2\\nPatient has adequate bone marrow and organ function . Patient is able to swallow and retain oral medication\\n\\n9. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;\\n\\nExclusion Criteria:\\n\\nHistory of hypersensitivity to LDE225, or to drugs of similar chemical classes.\\nPatient has received previous treatment with smoothened inhibitors.\\nPatients with known CNS (Central Nervous System) metastases or a primary CNS malignancy.\\nPatients who have neuromuscular disorders or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as HMG CoA (3-hydroxy-3-methyl-glutaryl Coenzyme A) inhibitors (statins), clofibrate and gemfibrozil.\\nPatients who are planning on embarking on new physical activities, such as strenuous exercise, that can result in significant increases in plasma CK (Creatine Kinase) levels while on study treatment.\\nPatients who require the use of coumarin derivates cannot be enrolled as LDE225 is a competitive inhibitors of CYP2C9 based on in-vitro data.\\nPatients with chronic use of corticosteroids\\nPatients who are not willing to avoid consumption of Seville oranges, grapefruit or grapefruit juice grapefruit hybrids, pomelos and exotic citrus fruits during the entire study and preferably 7 days before the first dose of study medications, due to potential CYP3A4 interaction with the study medications.\\nPatients who are not willing to stop taking herbal medications at least 7 days prior to the first dose of study treatment.\\nPatient is currently being treated with drugs known to be strong inhibitors or inducers of CYP3A4/5, which cannot be discontinued or switched to a different medication 7 days prior to starting study treatment and for the duration of the study..\\n\\nCurrent medical history of the following:\\n\\nHistory of or presence of clinically significant uncontrolled ventricular or atrial tachyarrhythmia\\nClinically significant resting bradycardia (< 45 beats per minute) or any primary of secondary heart block\\nHistory of unstable angina pectoris\\nClinically significant cardio-vascular disease (e.g. congestive heart failure NYHA Class III-IV (New York Heart Association), atherosclerosis, labile hypertension or uncontrolled hypertension\\nPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive HCG (Human Chorionic Gonadotropin) laboratory test\\nPatients who are not willing to apply highly effective contraception during the study and through the duration as defined below after the final dose of study treatment.\\nSexually active males who are unwilling to use a condom during intercourse while taking drug and for 6 months after stopping investigational medications and agree not to father a child in this period. Patients who in the investigators' opinion may be unwilling, unable or unlikely to comply with requirements of the study protocol\\nPatient is currently receiving increasing or chronic treatment with corticosteroids ((≥ the anti-inflammatory potency of 4mg dexamethasone) or another immunosuppressive agent.\\nPatient has been treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated before enrollment, may be continued\\nPatient who has received targeted therapy or immunotherapy ≤ 3 weeks (6 weeks for monoclonal antibodies) prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy\\nPatient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LDE225 (e.g., ulcerative colitis, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)\\nPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate patient participation in the clinical study.\\nHIV-positive patients on combination antiretroviral therapy.\\nPatients who in the investigators' opinion may be unwilling, unable or unlikely to comply with requirements of the study protocol\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02079623']\n",
      "Phase: []\n",
      "Start Date: ['November 2013']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients above 18 years old, who have given informed consent to treatment with electroporation\\nPerformance status <= 2 and meets one of the items below\\nPatients diagnosed with LAPC, who are not candidate to primary curative surgical treatment due to tumor invasion in surrounding blood vessels or adjacent organs\\nPatients, who have received oncological treatment with the aim of downstaging and the tumor still is deemed none-resectable\\n\\nExclusion Criteria:\\n\\nPatients with pacemaker or similar electrostimulator (TNS, anal sphincter stimulators ect.)\\nPatients for whom the anesthesia involves high risk (ASA- IV)\\nEstimated survival of less than 3 months\\nMetallic stent in the biliary tract, which can not be removed or changed to plastic stent.\\nPerformance status > 2.\\nPregnancy\\nEpilepsy or other condition involving convulsions\\nInability to give informed consent.\\nPatients with inability to cooperate for treatment and follow-up\\nSevere heart disease\\nPatients with a tumor larger than 5 cm.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01492907']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['January 2012']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nCancer cases are eligible for participation if all of the following criteria are met:\\n\\n1. Diagnosis or suspected diagnosis of pancreatic or periampullary cancer that is deemed to be operable and for which a pancreatectomy is planned.\\nAt least 18 years of age.\\n\\nAdequate hepatic function within 4 weeks of study enrollment defined as:\\n\\nBilirubin ≤ 2 mg/dl\\naspartate aminotransferase (ALT), alanine aminotransferase (AST), alkaline phosphatase ≤ 2 the upper limit of normal (ULN)\\nFemales of childbearing potential or males whose partners are of child bearing potential are required to use an effective method of contraception (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the study and for 2 weeks after MelQx administration.\\nVoluntary written consent before performance of any study-related procedure not part of normal medical care\\n\\nHealthy controls are eligible for participation if all of the following criteria are met:\\n\\nConsider themselves generally healthy.\\nAt least 18 years of age\\nControls will be gender and age matched within 10 years of cases.\\n\\nAdequate hepatic function within 4 weeks of study enrollment defined as:\\n\\nBilirubin ≤ 2 mg/dl\\nALT, AST, alkaline phosphatase ≤ 2 the upper limit of normal (ULN)\\nFemales of childbearing potential or males whose partners are of child bearing potential are required to use an effective method of contraception (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the study and for 2 weeks after MelQx administration.\\nVoluntary written consent before performance of any study-related procedure not part of normal medical care\\n\\nExclusion Criteria:\\n\\nCancer cases are not eligible for participation if any of the following criteria are met:\\n\\nFor the purposes of this study to reduce the risk of recruiting a potentially unresectable patient:\\n\\nTumor ≥ 3 cm by scan\\nCA-19-9 > 400\\nAscites\\nPregnant or lactating\\nUncontrolled chronic conditions such as: cardiovascular disease, hypertension, angina, congestive obstructive pulmonary disease (COPD) or other conditions which may alter metabolism, other than diabetes.\\n\\nHealthy controls are not eligible for participation if any of the following criteria are met:\\n\\nPregnant or lactating.\\nUncontrolled chronic conditions such as cardiovascular disease, hypertension, angina, COPD or conditions which may alter metabolism including diabetes.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03509298']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['April 12, 2018']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Advanced Pancreatic Cancer']\n",
      "Brief Title: ['Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\n18-75 years old\\nThe patient is diagnosed as advanced pancreatic cancer,MUC1 is positive\\nThere is at least one tumor should be measured,and length≥10mm of focus not at lymph node or length≥10mm of focus at lymph node\\nThe patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or local therapies\\nIf the patient received adjuvant chemotherapy after local treatment,the time should be more than 4 weeks after the end of chemotherapy, and disease progression or metastasis patients can also assigned into the group\\nThe time of surgical treatment≥ 3 months ;At the end of the intervention,radiotherapy and the end of the ablation time is more than 4 weeks\\nThe expected survival time ≥12 weeks\\nThe patient did not took any antitumor drugs within 4 weeks(any antitumor drugs, Chinese patent medicine including Delisheng injection,Kanglaite injection, Aidi injection\\nNo serious disease are conflicts with the solution(such as autoimmune disease,immunodeficiency,organ transplantation)\\nSign the informed consent\\n\\nExclusion Criteria:\\n\\nmedium or above ascites\\nPatient of second primary tumor or multiple primary cancer\\nPatients of T cell lymphoma、myeloma,and patients are using immunosuppressant\\nSystemic autoimmune diseases, allergic constitution or immunocompromised patients\\nPatients of chronic diseases need immune stimulant or hormone therapy\\nPatients of active bleeding or coagulant function abnormality（PT>16s、APTT>43s、TT>21s、INR≥2）,and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy\\nWomen who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test\\nPatients with brain、dura mater metastases or history of psychogenic\\nGastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy\\nPatients with severe stomach/esophageal varices and need for intervention treatment\\nPatients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment\\nPositive for HIV antibody\\nPatients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay\\nPatients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment\\nOther reasons the researchers think not suitable\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00526578']\n",
      "Phase: []\n",
      "Start Date: ['June 19, 2002']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Pancreatic Cancer Genetic Epidemiology (PACGENE) Study']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\n1) An effected or uneffected member of a family, age 18 or older, that has two or more reported pancreatic cancers in the family.\\n\\nExclusion Criteria:\\n\\nCases under age 18.\\nRelatives of pancreatic cancer cases under age 18.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03679910']\n",
      "Phase: []\n",
      "Start Date: ['January 1, 2019']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreas Cancer']\n",
      "Brief Title: ['Evaluation of CEMIP in Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nGroup 1:\\n\\nIncludes all patients presented by pancreatic cancer with clinical, radiological, laboratory diagnosis and pathological diagnosis.\\n\\nGroup 2:\\n\\nA: Healthy individual B: Individual with benign diseases such as benign hepatopancreatobiliary conditions as gall stones, obstructive calcular jaundice, chronic pancreatitis and benign gasrtrointestinal as ulcer and polyp.\\n\\nExclusion Criteria:\\n\\nPatients recently operated for pancreatic cancer.\\npatients diagnosed to have another type of cancer (Breast, gastric or colorectal).\\nHigh risk group of another type of cancer.\\nPatients with disseminated cancer.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05424159']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['July 1, 2022']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer Non-resectable']\n",
      "Brief Title: ['Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHave the ability to sign the written informed consent;\\nDuctal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;\\nDistant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC/UICC Version 8);\\nThe maximum diameter of pancreatic primary lesion and positive lymph node ≤7cm;\\nPancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);\\nEastern Cooperative Oncology Group (ECOG) performance score 0-1;\\nAdequate bone marrow function (neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥10.0g/dL);\\nAdequate liver function (total bilirubin <1.5 times the upper limit of normal value, aminotransferase <2.5 times the upper limit of normal value);\\nAdequate renal function (serum creatinine <2mg/dL, or creatinine clearance >50mL/min).\\n\\nExclusion Criteria:\\n\\nMultiple primary pancreatic lesions (>1);\\nTumor invaded the adjacent digestive tract;\\nRadiation therapy history;\\nOther local treatments history for pancreatic cancer, such as HIFU and irreversible electroporation;\\nThe irradiation dose of organs at risk cannot reach the dose constraint;\\nOther malignant tumors history;\\nInability to understand the purpose of treatment or unwillingness/inability to sign informed consent.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05500027']\n",
      "Phase: []\n",
      "Start Date: ['May 1, 2021']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Serum Biomarker', 'Pancreatic Cancer']\n",
      "Brief Title: ['sCD8, as a Novel Biomarker for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHealthy volunteers\\nStage I-IV pancreatic cancer patients with pathological diagnosis\\nPancreatic cancer patients before and 1 week after surgery\\nPancreatic cancer patients before and 1 week after bile drainage\\nIPMN patients with pathological diagnosis before and 1 week after surgery\\nMCN patients with pathological diagnosis before and 1 week after surgery\\nSPN patients with pathological diagnosis before and 1 week after surgery\\nPNEN patients with pathological diagnosis before and 1 week after surgery\\nChronic pancreatitis patients with pathological diagnosis\\nCholecystitis patients meeting clinical criteria\\nCholangitis patients meeting clinical criteria\\nAutoimmune diseases meeting clinical criteria\\n\\nExclusion Criteria:\\n\\nRefusal to participate\\nAge less than 18-year old and over 85-year old']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01744353']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['November 2012']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPathologically confirmed pancreatic ductal adenocarcinoma.\\nMetastatic or locally advanced disease.\\nNo prior treatment for pancreatic cancer\\nRadiographically measurable disease.\\nNo major surgery within 4 weeks of the start of study treatment. Patients must have recovered from the side effects of any major surgery at the start of study treatment. Laparoscopy and central venous catheter placement are not considered major surgery.\\nPatients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A\\nPreexisting neuropathy > grade 1.\\nNo prior invasive malignancy within the prior two years. However, patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer or asymptomatic prostate cancer) are eligible.\\nECOG performance status 0 or 1.\\nAge ≥ 18 years of age.\\nNot pregnant and not nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment.\\n\\nRequired Initial Laboratory Values:\\n\\nNeutrophils ≥ 1,500/μl\\nPlatelet count ≥ 100,000/μl\\nCreatinine ≤ 1.5 mg/dL -or- creatinine clearance ≥ 60 mL/min\\nTotal bilirubin ≤ 1.5 x ULN\\nAST (SGOT) & ALT (SGPT) ≤ 3.0 x ULN\\n\\nExclusion Criteria:\\n\\n-Patients with known brain metastases']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04736043']\n",
      "Phase: []\n",
      "Start Date: ['January 31, 2021']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer Resectable']\n",
      "Brief Title: ['Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\n18 years old or older\\nNewly discovered pancreatic cancer and not a relapse\\nDiagnosed with pancreatic cancer via EUS-FNA, EUS-FNB before surgery\\nPatients who can undergo surgery for pancreatic cancer\\nDiagnosed with pancreatic cancer from the final tissue pathology diagnosis after surgery\\nwho is in need of adjuvant chemotherapy after surgery\\nAble to make decisions for oneself for participation\\nHas obtained voluntary consent in written form (if 70 years of age or older, receive consent from the guardian as well)\\n\\nExclusion Criteria:\\n\\nNone']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00726037']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['October 2008']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nMale patients and nonpregnant, nonlactating female patient > 18 years old\\nHistologic diagnosis of pancreatic cancer with distant disease seen on CT or MRI with no prior chemotherapy or radiotherapy for a least 4 weeks\\nKarnofsky performance status equal to or greater than 70%\\nLife expectancy of at least 3 months.\\nNo uncontrolled pain\\nNo symptoms of bowel obstruction\\nWomen with child bearing potential must agree to use adequate contraceptives. If she should become pregnant she needs to inform the treating physician\\nAbility to give informed consent\\n\\nExclusion Criteria:\\n\\nPositive serologic testing for HIV, AIDS, human T-cell lymphotrophic virus type 1, hepatitis B, or hepatitis C.\\nHemoglobin <9g/dL; hematocrit <27%; platelets <100,000/ U/L without transfusion support\\nCreatinine > 1.8 mg/dL\\nSerum albumin < 2.0 mg/dL\\nAST > 3X ULN; ALT > 3X ULN\\nBilirubin > 1.8\\nUncontrolled angina, arrhythmias, bronchospasm, hypertension, or hypercalcemia.\\nCorticosteroid use within 28 days\\nChemotherapy or radiation within 28 days\\nBacteremia or other signs of active systemic infection\\nHistory of autoimmune disease']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT06054984']\n",
      "Phase: ['Early Phase 1']\n",
      "Start Date: ['September 7, 2021']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['TCR-T Cells in the Treatment of Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nTo be eligible for the study, patients must meet all of the following criteria:\\n\\nMale or female, aged 18-75 years;\\nPatients with advanced pancreatic cancer diagnosed by histology or cytology, patients who failed to respond to standard treatment, relapsed or voluntarily gave up;\\nPatients must have tumor tissue that expresses specific tumor antigens, such as mutations in RAS and/or TP53;\\nPatients must undergo HLA matching testing and meet the requirements of HLA matching.\\nAt least one measurable or evaluable lesion ≥15 mm according to RECIST1.1 criteria;\\nPatients with ECOG < 2 and life expectancy ≥3 months;\\na) Liver function: ALT/AST < 3 times the upper limit of normal value (ULN) and bilirubin ≤34.2μmol/L; b) renal function: creatinine < 220μmol/L; c) terminal oxygen saturation ≥95% in room air; d) Cardiac function: left ventricular ejection fraction (LVEF) ≥60%; e) Blood routine: absolute neutrophil count ≥ 1×109/L; Platelet count ≥70×109/L; Absolute lymphocyte count ≥100 cells /μL;\\nThe patients met the requirements of apheresis without any contraindications.\\nWomen of childbearing age who have a negative urine pregnancy test at screening and before starting dosing and who have agreed to use highly effective contraception for at least 100 days after infusion; Female participants must agree not to donate eggs (oocytes, oocytes) for assisted reproductive purposes during the study and for 90 days after receiving the last study drug;\\nMale subjects with a fertile partner must consent to use an effective barrier method of contraception for at least 100 days after infusion; Must agree not to donate sperm for at least one year;\\nSign an informed consent form.\\n\\nExclusion Criteria:\\n\\nPatients who met any of the following criteria were not eligible for inclusion in the study:\\n\\nPersons with severe mental disorders;\\nA positive virological test for any of the following: HIV; HCV; HBsAg; HBcAb was positive, and HBV DNA copy number and TPPA were positive.\\nPatients with severe allergic history or allergic constitution;\\nSevere underlying medical conditions such as evidence of other serious active viral, bacterial or uncontrolled systemic fungal infection; Active autoimmune disease or a history of autoimmune disease within 3 years;\\nA history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic immunosuppressive/systemic disease modulating drugs within the past 2 years;\\nCombined with organ dysfunction, such as renal insufficiency;\\nHad been enrolled in another clinical trial within 4 weeks before enrollment in the trial;\\nThose who were unable to comply with the study protocol and follow-up plan due to physiological, family, social, geographical and other factors;\\nPatients with contraindications to cyclophosphamide or fludarabine chemotherapy;\\nSubjects who required additional immunosuppressive drug therapy within 72 hours before TCR-T infusion, except for the treatment of adverse events during the trial;\\nPregnant, lactating women, or men who plan to have children while participating in the study or within 100 days of receiving study treatment;\\nAny other condition considered by the investigator to be ineligible for enrollment.\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05058846']\n",
      "Phase: []\n",
      "Start Date: ['January 20, 2022']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Carcinoma']\n",
      "Brief Title: ['Pilot Study of Pancreatic Cancer Screening']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAbility to provide consent and willing, and able to comply with study procedures Ability to read and speak English\\n\\nGROUP I:\\n\\nDocumentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation\\nNo strong family history of pancreatic cancer (defined as having >= 1 first-degree or second-degree relative with a history of pancreatic cancer)\\nAge >= 50 years old at time of consent.\\n\\nGROUP II:\\n\\nDocumentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation\\nHas strong family history of pancreatic cancer (defined as having >= 1 first-degree or second-degree relative with a history of pancreatic cancer)\\nAge >= 18 years old at time of consent (screening generally begins 10 years prior to the earliest pancreatic cancer in the family)\\n\\nExclusion Criteria:\\n\\nPrior or active pancreatic cancer. Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03460769']\n",
      "Phase: []\n",
      "Start Date: ['November 1, 2017']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer', 'Chronic Pancreatitis', 'Diabetes Mellitus Type 3c']\n",
      "Brief Title: ['Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nAll patients must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must have signed an authorization for the release of their protected health information.\\n\\nPatients must be ages ≥30 and <85.\\nPatients must have a diagnosis of one of the following based on study definitions\\nNew Onset Diabetes (<3 years) in subjects with Pancreatic Cancer (PDAC);\\nNew Onset Diabetes (<3 years) in subjects with Chronic Pancreatitis;\\nNew Onset Diabetes (<3 years) in subjects without Pancreatic disease (i.e., T2DM)\\nLong standing T2DM (≥3 years) without Pancreatic disease\\nLong standing diabetes (≥3 years) in subjects with PDAC\\nLong standing diabetes (≥3 years) subjects with chronic pancreatitis\\nnon-diabetic subjects with PDAC\\nnon-diabetic subjects with chronic pancreatitis\\nnon-diabetic controls without Pancreatic disease\\n\\nExclusion Criteria:\\n\\nSubjects must not have any significant medical illnesses (including diabetes) that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate study interventions.\\nDiabetes not stable enough to permit holding of diabetes medications in subjects undergoing mixed meal tolerance testing.\\nSubjects taking higher doses of insulin (≥0.75 unit/kg/day).\\nSubjects in the non-pancreatic disease subgroup (i.e., T2DM) on longer acting agents, including thiazolidinediones and once-weekly GLP-1 agonists (Bydureon [exenatide], Ozempic [semaglutide], Trulicity [dulaglutide]). Conversely, the use of these medications is permitted for subjects in the CP and PDAC groups.\\nPatients currently receiving oral steroid medications.\\nHospitalization for acute pancreatitis within 2 months before study visit (with the exception of subjects enrolled into the PDAC group, as this may be a symptom of the disease).\\nThe presence of a symptomatic cyst in subjects with CP. The presence of a cyst in subjects with pancreatic cancer is not an exclusion, including cancer arising from a mucinous cystic lesion.\\nAny subject with a known pancreatic cancer histologic subtype other than adenocarcinoma (e.g., subjects with pancreatic neuroendocrine tumors are excluded).\\nPrevious pancreatic surgery (including total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, enucleation, or Frey procedure). An exception to this criterion are subjects with CP who had a history of surgery (including pancreaticoduodenectomy, pancreatic ojejunostomy, distal pancreatectomy, or Frey).\\nPrevious treatment for pancreatic cancer, including chemotherapy or radiation.\\nPrevious vagotomy or gastric surgery, including endoscopic gastric reduction procedures.\\nPrevious diagnosis of gastroparesis.\\nPatients on treatment for any cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).\\nAllergy or intolerance to ingredients in Boost drink in subjects undergoing mixed meal testing\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00837135']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['January 2008']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['GI-4000 With Adoptive Transfer in Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAdult patients with untreated, locally advanced pancreatic adenocarcinoma that expresses a GI-4000 related k-ras oncoprotein.\\n\\nHistologically-confirmed pancreatic adenocarcinoma that expresses one of the GI-4000-related k-ras oncoproteins (G12V, G12C, G12D, Q61L, or Q61R)\\n\\nLocally advanced disease, (stages I-III, i.e no evidence of metastasis outside the pancreas and its regional lymph nodes). Preferred subjects for entry into the study are those with borderline resectable disease, as defined by:\\n\\ntumor that encases a short segment of the hepatic artery without extension to the celiac axis and that is amenable to resection and reconstruction, OR\\ntumor that abuts the superior mesenteric artery and that involves <180 degrees of the circumference of the artery, OR\\nshort-segment occlusion of the superior mesenteric vein, portal vein, or their confluence with a suitable option available for vascular reconstruction because the veins are normal above and below the area of tumor involvement.\\nAge >18 years\\nECOG performance status 0 or 1\\n\\nNormal organ and bone marrow function as defined by:\\n\\nAbsolute neutrophil count > 1,500/μl Platelets > 100,000/μl AST(SGOT)/ALT(SGPT)< 2.5 X institutional upper limit of normal Bilirubin < 2.0 mg/dL unless due to bile duct blockage by tumor Creatinine < 1.5 x ULN\\n\\nA biliary stent 9F or biliary bypass before treatment, if tumor-related biliary obstruction is present\\nThe ability to sustain adequate hydration and nutrition (>1500 cal/d) by oral intake or access for supplemental enteral feeding (nasoenteral tube, feeding jejunostomy or PEG)\\nPatients must have measurable disease by radiographic imaging, as defined by 1 lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 20 mm with conventional techniques or 10 mm with spiral CT scanning. Marker elevation alone is insufficient for entry.\\nAbility to understand and the willingness to sign a written informed consent documents.\\nAdequate venous or catheter access and ability to tolerate apheresis.\\n\\nExclusion Criteria:\\n\\nTumor metastatic to peritoneum, liver or other organs\\nTumor that is clearly resectable for curative intent\\nPrior chemotherapy, radiation therapy, targeted therapy, or immunotherapy for pancreatic cancer.\\nReceipt of any other investigational agents within 30 days prior to screening\\nKnown HIV positive\\nA major surgical procedure or significant traumatic injury within 28 days prior to anticipated initiation of chemotherapy, an anticipated major surgical procedure during the course of the study, or a minor surgical procedure (laparoscopy, fine needle aspiration, or core biopsy) within 7 days of anticipated initiation of chemotherapy.\\nSerious non-healing wounds, ulcers, or bone fractures\\nPregnancy or ongoing breast-feeding, as chemotherapy may pose substantial risk to the fetus/infant.\\nPatients whose treatment plan would require treating >50% of the liver to a dose greater than 30 Gy or treating > 50% of the total kidney volume to a dose greater than 18 Gy\\nPositive scratch test (immediate hypersensitivity, IgE mediated) to S. cerevisiae.\\nActive autoimmune disease requiring immunosuppressive therapy']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05168527']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['September 3, 2021']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nAge≥18 years old;\\nPancreatic cancer was confirmed by pathology or cytology;\\nLiver-metastatic confirmed by pathology or clinical imaging;\\nNewly treated patients who have not received any systemic treatment for pancreatic cancer are allowed to enter the group for patients who have previously used fluorouracils (excluding gemcitabine and or taxanes) as adjuvant treatments for recurrence;\\nECOG score of preoperative physical condition was 0-1;\\nExpected survival time ≥3months;\\nThere is at least one measurable lesion under CT evaluation according to the RECIST 1.1 standard,;\\n\\nThe patient has sufficient hematological function (not receiving blood, platelet transfusion or growth factor supportive therapy within 14 days before the start of the study treatment), determined according to the following laboratory test values:\\n\\nAbsolute neutrophil count (ANC) ≥ 1.5 × 109/L;\\nPlatelets ≥ 100 × 109/L;\\nHemoglobin ≥ 9.0 g/dL;\\n\\nThe patient has sufficient liver and kidney function, which is determined according to the following laboratory test values:\\n\\nSerum creatinine ≤ 1.5 × ULN;\\nIf serum creatinine>1.5 × ULN, creatinine clearance rate ≥50ml/min;\\nAlanine aminotransferase (AST) and aspartate aminotransferase (ALT) in non-liver metastatic lesions ≤ 2.5 × ULN, and AST and ALT ≤ 5.0 × ULN in liver metastatic lesions;\\nSerum albumin ≥ 2.5 g/dL;\\nTotal bilirubin ≤1.5 × ULN;\\nMen, women of childbearing age (postmenopausal women who must have been menopausal for at least 12 months to be considered infertile) and their partners voluntarily take it during treatment and at least six months after the last study drug is taken by the investigator. Effective contraceptive measures;\\nAble to understand and voluntarily sign a written informed consent form and voluntarily complete the research procedures and follow-up inspections. The informed consent form must be signed before the implementation of any research procedures specified by the trial\\n\\nExclusion Criteria:\\n\\nReceived chemotherapy within 14 days before entering the study.\\nReceived VEGFR signaling pathway therapy or other anti-cancer therapy within 14 days before enrollment.\\nReceived radiotherapy within 14 days before enrollment, and received chest radiotherapy within 28 days before enrollment.\\nActive central nervous system involvement is known.\\nOral anticoagulant is being used, or an inhibitor or inducer of potent cytochrome oxidase 3A4 (CYP3A4) is being used (see Appendix 1 for details). Allow the use of subcutaneous anticoagulants.\\nPatients who have participated in clinical trials of reagents or new drugs under investigation within 28 days before the first treatment administration (phase I-IV clinical trials).\\nAdverse reactions caused by previous anti-tumor treatments did not recover to grade 1 or below (hair loss and peripheral neuropathy did not recover to grade 2 or below).\\nActive infection or unexplained fever> 38.5°C occurred within 2 weeks before the first administration (according to the judgment of the investigator, the subject can be included in the group for fever caused by the tumor).\\nVarious chronic active infections, such as hepatitis B virus (evidence of hepatitis activity such as HBV-DNA ≥104 copies/ml or 2000IU/ml), hepatitis C and HIV.\\nPatients with elevated serum troponin T or I (above the normal limit specified by the research center).\\nPregnant or lactating (lactating) women, where pregnancy is defined as the state of a woman after conception until the end of pregnancy, and the result of a serum β-human chorionic gonadotropin (β-hCG) laboratory test is confirmed to be positive.\\nAny of the following cardiac standards: the average QTcF calculated according to Fridericia's formula during the rest period of the screening period [QTcF = QT/(RR1/3), RR is the standardized heart rate value, obtained by dividing 60 by the heart rate]: male> 450 milliseconds , Female> 470 milliseconds; any clinically important abnormalities in the rhythm, conduction or morphology of the resting electrocardiogram (ECG) (for example, complete left bundle branch block, third degree heart block, second degree heart block); Congenital long QT syndrome or family history of long QT syndrome.\\nAccording to the investigator's judgment, patients who have not fully recovered after surgery, patients whose wounds are in an active healing stage, patients who underwent major surgery within 28 days before the start of the study, and patients who underwent minor surgery within 14 days before the start of the study.\\nSevere and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results, including active opportunistic infections or advanced (severe) infections, and diabetes that cannot be controlled after adequate clinical anti-hyperglycemia treatment according to guidelines , Uncontrollable hypertension, cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, heart block above II, congestive heart failure (CHF), myocardial infarction in the past 6 months , Unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc.) or lung disease (history of interstitial pneumonia, obstructive lung disease and symptomatic bronchospasm).\\nAny other situation that the researcher considers inappropriate to participate in clinical research.\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01542177']\n",
      "Phase: []\n",
      "Start Date: ['February 2012']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer', 'Hypoxia']\n",
      "Brief Title: ['A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nMinimum age of 18 years old\\nHistologic diagnosis of pancreatic adenocarcinoma\\nTNM (7th edition) cT1-4, N0-1, M0-1\\nNo cytotoxic anti-cancer therapy for advanced / metastatic pancreatic cancer prior to study entry\\nAbility to provide written informed consent to participate in the study\\nECOG performance status 0, 1 or 2.\\nPatient should have the following blood counts at baseline: ANC equal or greater to 1.5 x 109/L; Platelets equal or greater to 100 x 109/L; Hgb equal or greater to 9g/Dl\\nPatient should have the following blood chemistry levels at baseline: AST (SGOT), ALT (SGPT) equal or less than 5 x upper limit of normal range (ULN) is allowed\\nPatient has an identifiable tumor (pancreatic tumor and/or metastasis) by imaging (CT scan and/or MR)\\nPatient must agree to use contraception considered adequate and appropriate by the investigator and if the patient is female of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (B-hCG)\\n\\nExclusion Criteria:\\n\\nInability to lie supine for more than 30 minutes\\nAny other type of primary cancer\\nLife expectancy of less than 12 weeks\\nPatient has known brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids and stable in two scans at least 4 weeks apart)\\nPatient has serious medical risk factors involving any of the major organ systems']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02459652']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['December 28, 2012']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nCytologic or histologic proof of pancreatic ductal carcinoma or adenosquamous carcinoma is required prior to study entry.\\nDisease assessment by Multi Detector-row Computed Tomography (MDCT) scan within 2 weeks of study entry\\nBorderline resectable pancreatic cancer\\nNo evidence of metastatic disease as determined by chest CT scan, and abdominal CT scan and laparoscopy. Paraaortic lymph node metastasis is considered as metastatic.\\nAge >/=20 years old, </=75 years old\\nEastern Cooperative Oncology Group (ECOG) performance status 0-1\\nNo prior chemotherapy or radiotherapy for pancreatic cancer\\nA square 10 x 10 cm radiation field could encompass all pancreatic lesions and lymph node metastases\\nAdequate oral intake\\nAppropriate biliary drainage for obstructive jaundice\\n\\nLab Values:\\n\\nhemoglobin concentration >/= 9.0 g/dL\\nleukocyte count >/= 3,000/mm3\\nplatelet count >/= 100,000/mm3\\nserum total bilirubin </= 2.0 mg dL, or </=3.0 mg/dL with biliary drainage\\nAspartate Transaminase (AST) and Alanine Transaminase (ALT) </= 100 U/L, or </= 150 U/L with biliary drainage\\nserum albumin >/= 3.0 g/dl\\nserum creatinine </= 1.2 mg dL\\nCreatinine clearance >/= 50 ml/min\\nWritten informed consent\\n\\nExclusion Criteria:\\n\\nTumor invasion to the alimentary tract determined by abdominal CT scan or endoscopic examination\\nPrior chemotherapy using fluoropyrimidine\\nPrior radiation therapy to the abdomen\\nWatery diarrhea\\nConcurrent phenytoin, warfarin potassium, or flucytosine treatment\\nPresence of contrast medium allergy\\nPulmonary fibrosis or interstitial pneumonia\\nPleural effusion or ascites\\nActive infection\\nUncontrolled diabetes mellitus (FBS >/= 200mg/dL or HbA1c >/= 10.0)\\nActive concomitant malignancy\\nActive gastroduodenal ulcer\\nSevere complications such as cardiac or renal disease\\nRegular administration of systemic corticosteroid\\nPsychiatric disorder\\nHistory of drug hypersensitivity\\nPregnant and lactating women and women of childbearing age who were not using effective contraception']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03398291']\n",
      "Phase: ['Phase 3']\n",
      "Start Date: ['July 1, 2018']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer', 'Liver Metastases', 'Surgery']\n",
      "Brief Title: ['Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy']\n",
      "EligibilityCriteria: [\"Note: This study has two steps. In the first step, patients who meet the criteria for candidates will receive standard first-line chemotherapy for pancreatic cancer. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was employed to measure tumor's response to chemotherapy every two cycles. Until some of them meet the criteria for intervention, they will be randomized and receive relevant interventions.\\n\\nInclusion Criteria for candidates:\\n\\nVoluntary participation\\n18-75 years old\\nEastern Cooperative Oncology Group (ECOG) 0-1\\nStage IV pancreatic cancer with no more than 3 liver metastases\\nHistologically confirmed diagnosis of pancreatic cancer\\nNo contraindication of chemotherapy\\n\\nExclusion Criteria for candidates:\\n\\nNot want to receive chemotherapy or potential operation.\\nMetastases at other sites except for liver\\nWith other malignancies\\nReceive chemotherapy, radiotherapy, and interventional therapy before\\nContraindication of potential operation\\n\\nInclusion Criteria for intervention:\\n\\nPrimary tumor and liver metastatic sites are both resectable.\\nNo new metastatic sites were observed\\nAbnormal serum tumor maker levels decreased by more than 50% after chemotherapy. In the serum tumor makers, carbohydrate antigen 19-9 (CA19-9) was always the first choice for evaluation and it should be below 500U/L after treatment. However, when the baseline CA19-9 was within the normal range, carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) were the alternative candidate indicators.\\n\\nExclusion Criteria for intervention:\\n\\n1. Contraindication of operation\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04161417']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['November 28, 2017']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Neoplasms Pancreatic']\n",
      "Brief Title: ['Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAdult patients (age >16 years).\\n\\nEither:\\n\\nPresence of a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT).\\n\\nOr\\n\\no Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.\\n\\nPatient is willing and able to undergo additional tumour biopsy (from the primary or a metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this is required.\\nPatient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery pending stage of disease at presentation.\\nPatient is deemed potentially eligible for a currently open PRIMUS study\\nPatient has signed informed consent for screening research tumour biopsy (Consent 1).\\nPatient has signed informed consent for Precision-Panc Master Protocol molecular profiling (Consent 2).']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02718859']\n",
      "Phase: ['Phase 1', 'Phase 2']\n",
      "Start Date: ['March 1, 2016']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAge:18-80\\nDiagnosis：advanced and active pancreatic cancer\\nThe tumour is measurable\\nEastern Cooperative Oncology Group(ECOG) score：0~2；3 but has no relationship with tumour\\n\\nVital organ function is normal:\\n\\ntotal bilirubin(TB) <68μmol/L aspartate aminotransferase(AST)<90 IU/L Cre<353μmol/L white blood cell count(WBC)<9×10^9/L,when WBC is close to or even greater than 9×10^9/L，the recommended dose should be halved platelet count(PLT)>80×10^9/L Red blood cell specific volume(HCT)>0.20 Non severe viral or bacterial infection\\n\\nNon pregnant and lactating patients\\nNon allergic reactions to biological products\\nInformed and consent\\n\\nExclusion Criteria:\\n\\nPatients with cardiac pacemaker\\nPatients with severe cardiac and pulmonary dysfunction\\nPatients that the researchers do not think fit into the group,including patients failed in compliance assessment']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05679583']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['September 26, 2022']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion criteria:\\n\\nHistologically diagnosed adenocarcinoma of the pancreas\\n\\nResectable pancreatic cancer at the time of diagnosis\\n\\nResectable pancreatic cancer refers to cases in which all of the following conditions are met:\\n\\nIf the tumor does not reach the superior mesenteric vein or portal vein, or even if it does, it reaches within 180°\\nIf the tumor does not reach the superior mesenteric artery, celiac artery, or common hepatic artery\\nIn the absence of distant metastases 3) Patients aged 20 years or older at the time of diagnosis 4) General performance status is 0-2 based on the Eastern Cooperative Oncology Group (ECOG) standard 5) Patients who voluntarily decided to participate in this clinical study and signed the written informed consent\\n\\nExclusion criteria:\\n\\nIf there is a history of radiation exposure to the abdomen\\nPancreatic cancer that cannot be resected\\nWhen accompanied by distant metastasis\\nPatients who are currently judged to be difficult to undergo surgery based on general performance status, bone marrow, and kidney function tests\\nPatients with active or uncontrolled infection\\nPatients with uncontrolled heart disease\\nPregnant or lactating women\\nPatients with a history of malignant tumor excluding skin epithelial carcinoma, except for malignant melanoma, stage 0 cervical cancer, and early thyroid cancer\\nPatients who have been treated for malignant tumors and have been cured for more than 5 years can participate in the study']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02654288']\n",
      "Phase: []\n",
      "Start Date: ['January 2016']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Neoplasms', 'Inflammation']\n",
      "Brief Title: ['Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAge ranging from 18 to 75-year old;\\nPathological verified pancreatic cancer including adenocarcinoma and cancerogenesis of intraductal papillary mucinous neoplasm (IPMN);\\nPancreatic cancer patients receiving adjuvant chemotherapy after curative resection; pancreatic cancer patients with recurrent lesions receiving chemotherapy after curative resection; pancreatic cancer patients with unresectable tumor receiving chemotherapy;\\nPatients have good physical status to receive chemotherapy;\\nNo history of chemotherapy and the current regimen contains gemcitabine;\\nNo medical history of IgG4 related diseases and other connective tissue diseases;\\nWritten consent is available.\\n\\nExclusion Criteria:\\n\\nPatient younger than 18-year old;\\nPatient has chemotherapy before;\\nThe physical status is too poor to receive chemotherapy;\\nThe patient has history of IgG4 related diseases and some other connective diseases;\\nWritten consent is not available.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00582062']\n",
      "Phase: []\n",
      "Start Date: ['March 2006']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Gastric and Pancreatic Cancer']\n",
      "Brief Title: ['Detection of Peritoneal Micrometastasis in Gastric and Pancreatic Cancer in Peritoneal Wash Samples']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nMen and women 18 years of age and older.\\nPresentation of gastric or pancreatic cancer based on objective findings on at least one of: CT scan; endoscopy; pathologic examination.\\nInformed consent, indicating the investigational nature of this study in keeping with the policies of Memorial Sloan-Kettering Cancer Center.\\nFor negative controls, any patient undergoing a laparoscopy for presumed benign disease (e.g., cholecystectomy, hernia repair, BSO)\\n\\nExclusion Criteria:\\n\\nUnder 18 years of age.\\nInability to speak or read English, and an appropriate translator is not identifiable.\\nUnable or unwilling to give informed consent.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00305760']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['December 2005']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"DISEASE CHARACTERISTICS:\\n\\nHistologically confirmed ductal adenocarcinoma of the pancreas\\n\\nMixed adenocarcinoma tumors eligible provided the predominant invasive component of the tumor is adenocarcinoma\\n\\nThe following histologic diagnoses are not eligible:\\n\\nAdenosquamous\\nSquamous cell\\nColloid\\nIslet cell\\nSerous or mucinous cystadenoma or cystadenocarcinoma\\nCarcinoid\\nSmall or large cell carcinoma\\nIntraductal oncocytic papillary neoplasms\\nOsteoclast-like giant cell tumors\\nAcinar cell carcinoma\\nPancreatoblastoma\\nSolid pseudopapillary tumors\\nUndifferentiated small cell carcinoma\\nNonepithelial tumors (sarcoma, gastrointestinal stromal tumor, lymphoma)\\nAdenocarcinomas of the ampulla, distal bile duct, or duodenum\\nMetastatic or locally advanced disease that is refractory to standard therapy OR for which patient refused standard therapy\\n\\nMeasurable disease defined as ≥ 1 lesion unidimensionally measured as ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan\\n\\nNo nonmeasurable disease only including, but not limited to, the following:\\n\\nBone lesions\\nLeptomeningeal disease\\nAscites\\nPleural or pericardial effusion\\nInflammatory breast disease\\nLymphangitis cutis/pulmonis\\nAbdominal masses that are not confirmed and followed by imaging techniques\\nCystic lesions\\nNo known active or untreated brain metastases\\n\\nPATIENT CHARACTERISTICS:\\n\\nECOG performance status 0-1\\nWBC ≥ 3,500/mm^3\\nAbsolute neutrophil count ≥ 1,500/mm^3\\nHemoglobin ≥ 9 g/dL\\nPlatelet count ≥ 90,000/mm^3\\nCreatinine ≤ 2.0 mg/dL\\nBilirubin ≤ 2 mg/dL\\nALT and AST ≤ 5 times upper limit of normal (ULN)\\nAlkaline phosphatase ≤ 5 times ULN\\nNo active infection\\nNo uncontrolled medical condition that would potentially increase the risk of toxicities or complications of study therapy\\nNo gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation\\nNo active peptic ulcer disease\\nNot pregnant or nursing\\nNegative pregnancy test\\nFertile patients must use effective contraception during and for 4 weeks after completion of study treatment\\nNo other malignancy within the past 5 years except for nonmelanomatous skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix\\nHIV negative\\n\\nNo active autoimmune disease or prior autoimmune disease requiring medical treatment with systemic immunosuppressants including any of the following:\\n\\nInflammatory bowel disease\\nSystemic vasculitis\\nScleroderma\\nPsoriasis\\nMultiple sclerosis\\nHemolytic anemia or immune thrombocytopenia\\nRheumatoid arthritis\\nSystemic lupus erythematosus\\nSjögren's syndrome\\nSarcoidosis\\nAsthma or chronic obstructive pulmonary disease that does not require systemic corticosteroids or routine use of inhaled steroids allowed\\nNo known or suspected hypersensitivity to sargramostim (GM-CSF), cyclophosphamide, pentastarch, corn, or DMSO\\nNo prior severe infusion reaction (> grade 3) to a monoclonal antibody\\n\\nPRIOR CONCURRENT THERAPY:\\n\\nSee Disease Characteristics\\nMore than 1 month since prior adjuvant chemotherapy\\nMore than 4 weeks since prior surgery except for minor procedures (e.g., dental work, skin biopsy) and biliary stent placement\\nNo prior surgical procedures affecting absorption\\nMore than 4 weeks since prior radiotherapy\\nMore than 1 month since prior participation in an investigational new drug study\\nNo unresolved chronic toxicity (except alopecia) from prior anticancer therapy\\nMore than 28 days since prior systemic steroids\\n\\nNo concurrent systemic steroids or immunosuppressive drugs\\n\\nTopical, inhaled, and intra-articular steroids allowed\\nNo other concurrent anticancer vaccine therapy\\nNo other concurrent chemotherapy, immunotherapy, radiotherapy, gene therapy, biologic therapy, or investigational therapy\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01995240']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['April 2013']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients with pancreatic tumors, with histological or cytological proof of adenocarcinoma or a high suspicion on CT imaging.\\nAny tumor with a size ≥ 1cm\\nWHO-performance score 0-2\\nWritten informed consent\\n\\nExclusion Criteria:\\n\\nAny psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol.\\nContra-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; or an aneurysm clip in their brain; patients with severe claustrophobia.\\nRenal failure (GFR < 30 ml/min) hampering safe administration of Gadolinium containing MR contrast agent.\\nFor the reproducibility part of the protocol: surgery, radiation and/or chemotherapy foreseen within the timeframe needed for MRI scanning.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02578732']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['July 12, 2016']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Locally Advanced Pancreatic Cancer', 'Pancreatic Cancer']\n",
      "Brief Title: ['FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPathologically or cytologically confirmed pancreatic ductal adenocarcinoma. Patients with pathology or cytology showing carcinoma of pancreas or adenosquamous of the pancreas are also eligible.\\nLocally advanced pancreatic cancer, including patients defined by Callery19 as \"unresectable\" and \"borderline resectable\" are eligible:\\nMeasurable disease as per RECIST 1.1\\nNo prior chemotherapy for pancreatic cancer.\\nNo major surgery within 3 weeks of the start of study treatment. Patients must have recovered from the side effects of any major surgery at the start of study treatment. For questions on if a surgery is deemed \"major,\" definition by surgeon can be used for clarification. Laparoscopy and central venous catheter placement are not considered major surgery.\\nNo prior invasive malignancy within the prior two years. However, patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer or asymptomatic prostate cancer) are eligible.\\nECOG performance status 0 or 1.\\nAge ≥ 18\\nNot pregnant and not nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment. Post-menopausal women (surgical menopause or lack of menses >24 months) do not need to have a pregnancy test, please document status.\\nWomen of childbearing potential and sexually active males must use an effective contraception method 28 days prior to treatment, during treatment and for three months after completing treatment (men are to use contraception for six months post last dose of drug). Documentation of this being discussed required.\\n\\nRequired Initial Laboratory Values:\\n\\nNeutrophils ≥ 1,500/mm3\\nPlatelet count ≥ 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)\\nHemoglobin > 9.0g/dL\\nCreatinine ≤ 1.5 mg/dL -or- creatinine clearance ≥ 60 mL/min\\nTotal bilirubin <1. 5 x ULN\\nAST (SGOT) & ALT (SGPT) ≤ 2.5 x ULN\\nAlkaline phosphatase < 2.5xULN. (Patients with elevated alkaline phosphatase, total bilirubin, AST and ALT, who have subsequently undergone biliary stenting and their liver tests are improving, do not need to wait for their alkaline phosphatase to become < 2.5x ULN if their total bilirubin, AST and ALT have improved to within required study levels and the alkaline phosphatase is decreasing.)\\n\\nExclusion Criteria:\\n\\nPatients with metastatic disease\\nPrior hypersensitivity to Oxaliplatin or Abraxane ® that in the investigators opinion would put the patient at risk if re-exposed\\nPreexisting neuropathy is not allowed from any cause.\\nPatients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A\\nPatients with unstable biliary stents or with plastic stents. Information on type of stent is required at registration.\\nPatients with active infection or fever (patients on antibiotics for infection or patients getting over a cold or seasonal virus are not excluded), or known historical or active infection with HIV, hepatitis B, or hepatitis C.\\nPatients with active sepsis or pneumonitis.\\nPatients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies that in the investigator\\'s opinion would put the patient at an increased risk.\\nUncontrolled diabetes. If patient has diabetes, confirmation on status (controlled or uncontrolled) required at registration.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00489671']\n",
      "Phase: []\n",
      "Start Date: ['June 2003']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer', 'Precancerous Condition']\n",
      "Brief Title: ['Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis']\n",
      "EligibilityCriteria: ['DISEASE CHARACTERISTICS:\\n\\nClinical diagnosis of chronic pancreatitis\\nBeing seen in the Department of Gastroenterology at Wake Forest University Baptist Medical Center\\n\\nPATIENT CHARACTERISTICS:\\n\\nNo type II diabetes\\nAble to understand and respond to questionnaire\\nAble to provide urine specimen\\nSpeaks English\\n\\nPRIOR CONCURRENT THERAPY:\\n\\nNot specified']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02050178']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['November 2013']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer', 'Stage IV Pancreatic Cancer']\n",
      "Brief Title: ['Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nSigned Informed Consent Form\\nAge ≥18 years\\nHistologically documented Stage IV ductal adenocarcinoma of the pancreas\\nAvailability of FFPE tumor tissue, either archival or obtained at study entry through fresh biopsy\\nTumor tissue from fine needle aspiration is not acceptable.\\nECOG performance status of 0 or 1\\nAdequate hematologic and end-organ function\\nEvaluable or measurable disease per RECIST v1.1\\nFor women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception\\n\\nExclusion Criteria:\\n\\nPrior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer\\nPrior adjuvant therapy for the treatment of ductal adenocarcinoma of the pancreas\\nKnown hypersensitivity to any component of study treatments\\nKnown brain metastases, uncontrolled seizure disorder, or active neurologic disease\\nLeptomeningeal disease as a manifestation of cancer\\nActive infection requiring antibiotics\\nBisphosphonate therapy for symptomatic hypercalcemia\\nKnown history of clinically significant liver disease, including active viral hepatitis and cirrhosis\\nSignificant intercurrent illness including, but not limited to, unstable angina pectoris, and cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements\\nPregnancy, lactation, or breastfeeding\\nKnown HIV infection\\nEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\\nConcurrent use of therapeutic warfarin\\nHistory of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis\\nNew York Heart Association Classification III or IV\\nKnown clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease\\nMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the study\\nOsteoporosis based on a T-score of <-2.5 at the left or right total hip, left or right femoral neck or lumbar spine (L1-L4) as determined by DEXA scan\\n\\nBone metastases and one of the following:\\n\\nPrior history of a pathologic fracture\\nLytic lesion requiring an impending orthopedic intervention\\nLack of treatment with a bisphosphonate or denosumab\\nTreatment with a thiazolidinedione PPAR gamma inhibitor; e.g. Actos® (pioglitazone) and Avandia® (rosiglitazone)\\nActive treatment with an oral or IV glucocortocoid for ≥4 weeks at a daily dose equivalent to or greater than 7.5 mg of oral prednisone\\nFasting β-CTX of >1000 pg/mL\\nMetabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02005315']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['September 2013']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer', 'Stage IV Pancreatic Cancer']\n",
      "Brief Title: ['A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nSigned Informed Consent Form\\nAge ≥18 years\\nHistologically documented Stage IV ductal adenocarcinoma of the pancreas\\nAvailability of tumor tissue, either archival FFPE or obtained at study entry through fresh biopsy\\nECOG performance status of 0 or 1\\nAdequate hematologic and end-organ function\\nEvaluable or measurable disease per RECIST v1.1\\nFor women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception\\n\\nExclusion Criteria:\\n\\nPrior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer\\nPrior adjuvant therapy for the treatment of ductal adenocarcinoma of the pancreas\\nKnown hypersensitivity to any component of study treatments\\nKnown brain metastases, uncontrolled seizure disorder, or active neurologic disease']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01063192']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['November 2009']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Locally Advanced Pancreatic Cancer']\n",
      "Brief Title: ['A Study of Locally Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients must have histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas.\\nPatients must have locally advanced pancreatic cancer (LAPC).\\nPatients must have LAPC evaluated by radiologist and/or surgeon according to either abdominal CT or MRI, or intra-operative findings.\\nPatients must have measurable disease.\\nAge >20 years.\\nECOG performance scale of 0-2.\\nPatients must have normal organ and marrow function.\\nPatients who present with jaundice, temporary or permanent internal / external drainage before enrollment will be allowed.\\nThe effects of study agents on the developing human fetus at the recommended therapeutic dose are unknown. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\\nAbility to understand and the willingness to sign a written informed consent document.\\n\\nExclusion Criteria:\\n\\nPatients with distant metastases are not eligible.\\nPatients may not be receiving any other investigational agents.\\nPatients who have had prior chemotherapy or radiotherapy are not eligible.\\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents used in the study.\\nPatients who have above grade II peripheral neuropathy.\\nPatients who had non-curable second primary malignancy.\\nUncontrolled intercurrent illness including.\\nPregnant women are excluded from this study because the study agents has the potential for teratogenic or abortifacient effects.\\nThose who are immuno-compromised or receiving immuno-suppressive therapy are excluded from the study.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05604573']\n",
      "Phase: []\n",
      "Start Date: ['February 9, 2022']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins\\nPatients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule\\nAmong patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control group\\n\\nExclusion Criteria:\\n\\nWhere the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form\\nIf a laboratory test is impossible due to a qualitative problem with the collected blood sample\\nWhere the collected tissue does not contain tissue of the desired malignant or benign disease']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00661882']\n",
      "Phase: []\n",
      "Start Date: ['February 2003']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Pancreatic Cancer Collaborative Registry']\n",
      "EligibilityCriteria: ['Patients Participants Inclusion Criteria:\\n\\nMust meet 1 of the following criteria:\\n\\nHistologically confirmed adenocarcinoma of the pancreas\\n\\nResectable stage I-IIA disease or stage IIB or higher disease Must have undergone complete surgical resection of the tumor with curative intent\\nPancreatic mass (solid) that is less than 4 cm as determined by any conventional imaging (MRI, EUS, or CT scan)\\nNo evidence of extension of the mass beyond the pancreas including vascular invasion or invasion into surrounding organs, with the exception of the bile duct\\nNo imaging evidence of metastatic disease or lymphadenopathy (lymph nodes greater than 1 cm and/or appearance suspicious for an advanced lesion by imaging criteria)\\nHas a family history of pancreatic cancer and is considered to be an at-risk individual for the disease (i.e., member of a family with 2 or more individuals with pancreatic cancer)\\n\\nPatients Participants Exclusion Criteria:\\n\\nNo prior malignancy, except nonmelanoma skin cancer, for 10 years\\nNo prior preoperative chemoradiotherapy (neoadjuvant)\\n\\nControl participants Inclusion Criteria:\\n\\nMust meet 1 of the following criteria:\\n\\nChronic pancreatitis OR history of exocrine insufficiency meeting the following criteria:\\n\\no At least 2 of the following criteria are met (unless patient has a history of pancreatic exocrine insufficiency in which case only 1 criterion must be met): Abdominal ultrasound that is consistent with chronic pancreatitis by standard radiological criteria (i.e., echogenic foci in the parenchyma, large or small cavities, calcifications, or dilated pancreatic duct) Abdominal CT scan consistent with chronic pancreatitis by standard radiological criteria (i.e., calcifications, dilated pancreatic duct, irregular contour of the gland, or cystic lesions) Endoscopic retrograde cholangiopancreatography exam consistent with chronic pancreatitis by standard radiological criteria (i.e., dilated tortuous main pancreatic duct with irregular secondary branches or intraductal calculi) Endoscopic ultrasound consistent with chronic pancreatitis by standard radiological criteria (i.e., echogenic foci, focal regions of decreased echogenicity, or pancreatic ductal changes)Pancreatic calcifications identified on plain film of the abdomen\\n\\nMust have an imaging study of the pancreas within 3 months of study enrollment that does not suggest a pancreatic mass\\nStable clinical history over the past year with no suspicion for cancer due to weight loss, jaundice, or change in abdominal symptoms\\nAcute biliary obstruction (stones) including jaundice of benign etiology meeting the following criteria:\\nElevation of serum bilirubin level greater than 2.0 mg/dL\\nDilated extrahepatic biliary systems demonstrated on US, MRI, or CT scan\\nBlood sample available within 72 hours of admission and prior to any corrective intervention\\nBiliary obstruction must be of benign etiology such as common bile duct stone or benign biliary stricture\\nMust have complete imaging study performed of the pancreas that does not suggest a pancreatic cancer (i.e., discrete mass lesion)\\nAge, race, and sex-matched to qualified pancreatic cancer cases\\n\\nControl Participants Exclusion Criteria:\\n\\nNo family history of pancreatic cancer\\nNo personal history of acute pancreatitis or biliary obstruction (stones) including jaundice of benign etiology\\nNo concurrent abdominal pain\\nNo concurrent unexplained weight loss']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03001505']\n",
      "Phase: []\n",
      "Start Date: ['May 4, 2017']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Registry for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPancreatic cancer\\n\\nExclusion Criteria:\\n\\nYounger than 18 years of age']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01056601']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['September 2010']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHistological diagnosis of locally advanced or metastatic pancreatic cancer (except neuroendocrine tumors, but including ampullary cancer) with progression after standard first line therapy that included gemcitabine (single agent or combination)\\nMeasurable disease on computated tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) criteria\\nAt least 28 days from previous systemic therapy, including investigational agents and 1st dose of study treatment and recovered from any acute toxic effects of that treatment before study enrollment.\\nHas Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 - Ability to provide written consent\\n\\nMust meet hematology and biochemistry laboratory criteria within 14 days of study enrollment:\\n\\nNeutrophil count >1500/mm^3\\nPlatelet count >100,000/mm^L\\nHemoglobin > or = 9 g/dL\\nAspartate aminotransferase (AST/SGOT) or Alanine transaminase (ALT/SGPT) < or = 2.5 times upper limit of normal (ULN)or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement\\nSerum bilirubin < or = 1.5 x ULN\\nSerum creatinine < or = 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min\\nTotal serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal (LLN)\\nSerum phosphorus > or = LLN\\nSerum potassium > or = LLN\\nSerum sodium ≥ LLN\\nSerum magnesium ≥ LLN\\nSerum albumin ≥ LLN or 3g/dl\\nPatients with any elevated Alkaline Phosphatase due to bone metastasis can be enrolled\\nBaseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstration left ventricular ejection fraction (LVEF) > or = 50%\\nNormal thyroid function within normal limits. Note: Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.\\nWomen of childbearing potential (WOCBP) must have a negative pregnancy tests within 7 days of study treatment administration and willing to use 2 methods of contraception\\n\\nExclusion Criteria:\\n\\n> 1 prior systemic treatment regimen for pancreatic cancer\\nPrior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein 90 (HSP90) inhibitors or valproic acid for treatment of cancer\\nAnyone needing valproic acid for any medical condition during the study or 5 days prior to panobinostat treatment\\n\\nImpaired cardiac function\\n\\nComplete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (<50 beats per minute), QTcF > 450 msec on screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular block)\\nPresence of atrial fibrillation (ventricular heart rate >100 bpm)\\nPrevious history angina pectoris or acute myocardial infarction (MI) within 6 months of study enrollment\\nCongestive heart failure (New York Heart Association functional classification III-IV) or baseline MUGA/Echo shows LVEF < 50%\\nUncontrolled hypertension defined as hypertensive blood pressure of SBP > 140 or DBP > 90, despite antihypertensive medications\\nHistory of deep vein thrombosis (DVT), pulmonary emboli or other blood clotting abnormality within 3 months of study enrollment\\nOngoing need for anti-coagulation therapy except daily low dose aspirin (≤ 100 mg/day) or low molecular weight heparin\\nConcomitant use of drugs with risk of causing torsades de pointes\\nAnyone with unresolved diarrhea > or = grade 2 at time of enrollment\\nImpairment of gastrointestinal function or disease that may significantly alter the absorption of panobinostat\\nGrade 2 or greater peripheral neuropathy within 14 days of enrollment\\nSerious concomitant medical or psychiatric disorders (e.g., active infection, uncontrolled diabetes)\\nPatients who have received chemotherapy, any investigational agent or undergone major surgery < 4 weeks prior to starting study drug\\nMale patients whose sexual partners are WOCBP and not using double method of contraception during the study and 3 months following.\\nKnown positivity for human immunodeficiency virus (HIV) or hepatitis C\\nHypersensitivity to bortezomib, boron or mannitol History of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03724435']\n",
      "Phase: []\n",
      "Start Date: ['December 6, 2019']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nProvision of signed and dated informed consent form\\nStated willingness to comply with all registry procedures and availability for the duration of the registry\\nHistology proven pancreatic carcinoma in any area of pancreas\\nPancreatic tumor that can be treated by FUS\\nWillingness and ability to complete follow-up interviews\\n\\nExclusion Criteria:\\n\\nAny disease, condition or surgery which would result in a contraindication to undergoing FUS therapy.\\nClinical trials of pancreatic cancer not of focused ultrasound or related activities\\nOther non-pancreatic cancer clinical trials']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04247503']\n",
      "Phase: []\n",
      "Start Date: ['December 11, 2019']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Familial Pancreatic Cancer']\n",
      "Brief Title: ['Cohort Study of Pancreatic Cancer Risk']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAn individual who has previously consented to the Biospecimen Resource for Pancreas Research (Substudy #2 Family Studies) - IRB 355-06\\n\\nIndividual who does not have a personal history of pancreatic cancer and meets one of the following:\\n\\nHas relatives in family that contains pancreatic cancer, and carries a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53.\\n\\nOR\\n\\nIs a first- or second-degree blood relative of an individual with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) and this PDAC patient has a germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53.\\n\\nOR\\n\\nIs a first- or second-degree blood relative of an individual with a germline mutation in one of these genes and where the mutation carrier is also a first-degree relative to a PDAC case.\\n\\nOR\\n\\nIs a blood relative to a PDAC patient in a family that contains three blood relatives (all maternal side or all paternal side) with PDAC.\\n\\nAge\\n\\n50 or older, OR\\nOr within 10 years of the age of diagnosis of the youngest PDAC blood relative.\\nIndividual with a valid United States mailing address. -\\n\\nExclusion Criteria:\\n\\nIndividual who has a personal history of PDAC\\nIndividual who has received a bone marrow transplant, who has had a blood transfusion within the last 7 days, or who has an active hematologic malignancy (i.e., leukemia or lymphoma).\\nIndividual who is unable to sign the informed consent because of mental incompetency or psychiatric illness\\nIndividual who is non-English speaking\\nIndividual who is a prison inmate -']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04931394']\n",
      "Phase: ['Phase 3']\n",
      "Start Date: ['June 1, 2021']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAge≥18 years old and ≤80 years old.\\nComplete R0 resection for pancreatic cancer with no evidence of malignant ascites, peritoneal metastases or distant metastases.\\nHistology confirmed pancreatic adenocarcinoma.\\nEligible histologic variants include adenocarcinoma or variants to include mucinous adenocarcinoma or adenosquamous carcinoma.\\nNo metastases are found in preoperative examination.\\nNo prior chemotherapy or radiotherapy.\\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\\nLife expectancy of greater than 90 days, as judged by the investigator.\\nRoutine blood test: absolute neutrophil count>1500/mm3, platelet>100000/mm3.\\nNormal liver function: serum total bilirubin≤2.0mg/dl, aminotransferase (ALT) and aspertate aminotransferase (AST) <2.5 times of the upper limit of normal value.\\nNormal kidney function: serum creatinine<1.5 times of the upper limit of normal value or creatinine clearance rate>45ml/min.\\nThe pancreatic cancer organoid were cultured successfully.\\nNo severe comorbidities.\\n\\nExclusion Criteria:\\n\\nPatients with poor condition can not tolerate chemotherapy and targeted therapy.\\nImpaired organ functions: heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.\\nPatients diagnosed with other cancer within 5 years.\\nPatients who are pregnant or breastfeeding.\\nPatients enrolled in other clinical trials or incompliant of regular follow up.\\nPatients who did not provide an informed consent.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05724992']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['December 20, 2022']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Candidates for Hereditary Pancreatic Cancer Testing']\n",
      "Brief Title: ['Familial Pancreatic Cancer PROPHilation Program in Italy']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nBeing enrolled on the IRFARPC registry\\nHaving familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)\\nWillingness to participate in saliva-swab-based genetic testing\\n\\nExclusion Criteria:\\n\\n- Already known genetic mutation']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00255827']\n",
      "Phase: ['Phase 1', 'Phase 2']\n",
      "Start Date: ['November 2005']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Vaccine Treatment for Surgically Resected Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nA histological diagnosis of adenocarcinoma or other exocrine carcinoma of the pancreas. The patient's pathology must be reviewed and confirmed by Northwestern University's Pathology Department.\\nAJCC Stage I or II Pancreatic carcinoma. Patients must have undergone surgical resection for the tumor.\\nEastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.\\nSerum albumin greater than or equal to 2.5 gm/dL.\\nExpected survival greater than or equal to 6 months.\\nSubjects must have a negative serology for Hep B, C and HIV prior to entering study.\\nAll On-Study Tests must be less than or equal to Grade I toxicity for patient to be eligible for study, excluding serum LDH levels. PT, PTT must be less than or equal to 1.5 x ULN except for patients who are on therapeutic anticoagulant therapy.\\nAdequate organ function including:\\n\\nMarrow: hemoglobin greater than or equal to 10.0 gm/dL, absolute granulocyte count (AGC) greater than or equal to 1500/mm3, platelets greater than or equal to 100,000/mm3, absolute lymphocyte count greater than or equal to 475/mm3.\\n\\nHepatic: serum total bilirubin less than or equal to 1.5 x ULN mg/dL, ALT (SGPT) and AST (SGOT) less than or equal to 2.5 x upper limit of normal (ULN).\\n\\nRenal: serum creatinine (sCr) less than or equal to 2.0 x ULN, or creatinine clearance (Ccr) greater than or equal to 30 mL/min.\\n\\nPrior therapy for pancreatic cancer that may include surgery and/or different neoadjuvant chemotherapy or adjuvant chemo-radiation regimens, or radiation therapy. Patients who undergo surgical resection and refuse chemotherapy or radiation therapy will be eligible.\\nPatients must be greater than or equal to 4 weeks since surgery if treated with neoadjuvant therapy or greater than or equal to 4 weeks since conclusion of chemo-radiation if treated with post-operative adjuvant therapy and recovered from the toxicity of prior treatment to less than or equal to Grade I, exclusive of alopecia or fatigue.\\nPatients must have the ability to understand the study, its inherent risks, side effects and potential benefits and be able give written informed consent to participate. Patients may not be consented by a durable power of attorney (DPA).\\nAll subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product, and for one month after the last immunization.\\n\\nExclusion Criteria:\\n\\nAge <18-years-old.\\nActive metastases.\\nHypercalcemia > 2.9 mmol/L, unresponsive to standard therapy (e.g., I.V. hydration, diuretics, calcitonin or bisphosphonate therapy).\\nOther malignancy within five years, unless the probability of recurrence of the prior malignancy is <5%. Patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.\\nHistory of organ transplant or current active immunosuppressive therapy (such as cyclosporine, tacrolimus, etc.).\\nSubjects taking systemic corticosteroid therapy for any reason are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require systemic corticosteroids after beginning vaccination, will be removed from study.\\nSignificant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.\\nActive infection or antibiotics within 1-week prior to study, including unexplained fever (temp > 38.1C).\\nAutoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), etc.). Patients with a remote history of asthma or mild active asthma are eligible.\\nOther serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., liver cirrhosis) or a serious illness in medical opinion of the clinical investigator.\\nAny condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.).\\nA known allergy to any component of the alpha(1,3)galactosyltransferase tumor vaccine or cell lines.\\nPrior splenectomy.\\nPregnant or nursing women due to the unknown effects of vaccination on the developing fetus or newborn infant. (For patients with child bearing potential, a βHCG must be completed within 7 days of first vaccination).\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04777604']\n",
      "Phase: []\n",
      "Start Date: ['March 1, 2021']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreas Cancer']\n",
      "Brief Title: ['Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\n18 years old or older\\nNewly discovered pancreatic cancer and not a relapse\\nDiagnosed with pancreatic cancer via EUS-FNA, EUS-FNB before surgery\\nwho is in need of neoadjuvant chemotherapy before surgery\\nPatients who can undergo surgery for pancreatic cancer after neoadjuvant chemotherapy\\nDiagnosed with pancreatic cancer from the final tissue pathology diagnosis after surgery\\nAble to make decisions for oneself for participation\\nHas obtained voluntary consent in written form (if 70 years of age or older, receive consent from the guardian as well)\\n\\nExclusion Criteria:\\n\\n• None']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02277834']\n",
      "Phase: []\n",
      "Start Date: ['August 2014']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:Group A:\\n\\nMale or females that have suspected pancreatic adenocarcinoma, localized or metastatic.\\nThe pancreatic adenocarcinoma must be active, with active intra-pancreatic tumor documented within the last 3 months by CT or MRI scan.\\nAt least 19 years of age. (All Cohorts)\\nIn the Investigator's judgment, participant is mentally competent to provide informed consent to participate in the study. (All Cohorts)\\nEastern Cooperative Oncology Group(ECOG) performance status of 0-2. (All Cohorts)\\nNegative urine pregnancy test at screening, if applicable. (All Cohorts)\\nThe patient must already have a completed, active consent for either endoscopic ultrasound(EUS) and/or endoscopic retrograde cholangiopancreatography (ERCP) at University of Alabama at Birmingham(UAB). (All Cohorts)\\n\\nGroup B:\\n\\nMale or female patients that have had chronic pancreatitis for at least 6 months.\\nCT abdomen or MRI abdomen within the last 3 months demonstrating no suspicion of pancreatic adenocarcinoma.\\n\\nGroup C:\\n\\n1.Male or female patients already scheduled to undergo upper endoscopy for non-pancreatic, non-neoplastic indications.\\n\\nExclusion Criteria:Group A:\\n\\nThe participant is medically unfit to undergo upper endoscopy.\\nNo cancer-directed therapy administered within the last 3 months. This includes any of the following: surgical resection, chemotherapy, radiation therapy, immunologic or biologic therapy.\\nParticipants with a known allergy to secretin.\\nParticipants who are pregnant or lactating, or intending to become pregnant during the study.\\nParticipants of childbearing potential who refuse a pregnancy test.\\nParticipants who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.\\nParticipants who have participated in an investigational surgical, drug, or device study within the past 30 days.\\nParticipants who currently have a biliary stent in place.\\nMental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\\nThe endoscopic pancreatic biopsy does not show adenocarcinoma.\\n\\nGroup B:\\n\\nThe participant is medically unfit to undergo upper endoscopy.\\nThe participant has a suspicion of pancreatic adenocarcinoma on imaging within the last 3 months.\\nParticipants with a known allergy to secretin.\\nParticipants who are pregnant or lactating, or intending to become pregnant during the study.\\nParticipants of childbearing potential who refuse a pregnancy test.\\nParticipants who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.\\nParticipants who have participated in an investigational surgical, drug, or device study within the past 30 days.\\nParticipants who currently have a biliary stent in place.\\nMental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\\n\\nGroup C:\\n\\nThe participant is medically unfit to undergo upper endoscopy.\\nThe participant has a history of, or current clinical suspicion of pancreatic adenocarcinoma or pancreatitis.\\nThe participant has a history of any type of gastrointestinal malignancy within the last 5 years.\\nParticipants with a known allergy to secretin.\\nParticipants who are pregnant or lactating, or intending to become pregnant during the study.\\nParticipants of childbearing potential who refuse a pregnancy test.\\nParticipants who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.\\nParticipants who have participated in an investigational surgical, drug, or device study within the past 30 days.\\nParticipants who currently have a biliary stent in place.\\n\\nMental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\\n\\n-\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04498689']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['August 1, 2019']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\n1. Signed informed consent form obtained prior to treatment. The patients were fully explained and understood the purpose, contents, predicted efficacy, pharmacological effects, and risks of this study.\\n\\n2. target patients\\n\\nthe patients were histopathologically- or cytocologically-confirmed as metastatic pancreatic cancer.\\nAt least one measurable objective lesion (both primary and metastatic) was identified based on the RECIST 1.1 criteria;\\nEastern Cooperative Oncology Group (ECOG) performance status 0-1;\\nThe expected survival after surgery ≥ 3 months\\nThe subjects have good compliance, can be treated and followed up, and voluntarily comply with the relevant provisions of this study\\nNo contraindications for camrelizumab, gemcitabine and nab-paclitaxel. 3. Age and reproductive status\\nMale and female patients at the age of 18-75\\nSubjects of child-bearing age must agree to take effective contraceptive measures during the study period; Serum or urine pregnancy tests must be negative for women of childbearing age 24 hours before the start of therapy;\\n\\nWomen must not lactate.\\n\\nExclusion Criteria:\\n\\n1. The target disease has cerebral metastasis; 2. Previously treated by anti-PD-1 or anti-PD-L1 drugs; 3. Received any investigational drug within 4 weeks before the first use of the research drug; 4. Enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or an interventional follow-up clinical study; 5. medical history and complications\\n\\npatients had uncontrolled serious medical condition that the investigator considered may affect the subject's to receive treatment under the study program. For example, patients with severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.\\npatients who are suffering active, known or suspected autoimmune diseases (including but limited to uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchodilator therapy, etc.). Subjects with hypothyroidism who only need hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss) can be enrolled;\\nPatients who are suffering from active tuberculosis infection: Patients with active pulmonary tuberculosis infection within 1 year before medication should be excluded even if they have been treated; patients with a history of active tuberculosis infection more than 1 year ago should also be excluded unless it is proven that they have received standard anti-TB treatment before;\\nPatients who have previous interstitial lung disease or (non-infectious) pneumonia and requires oral or intravenous steroid therapy;\\nPatients who need to receive long-term systemic hormones (dose equivalent to >10mg prednisone/day) or any other form of immunosuppressive therapy. Subjects using inhaled or topical corticosteroids can be enrolled;\\n\\nPatients who have uncontrolled heart disease, such as:\\n\\nNew York Heart Association (NYHA) level 2 heart failure;\\nUnstable angina;\\nMyocardial infarction occurred within 1 year\\nSupraventricular or ventricular arrhythmias that have clinical significance and require treatment or intervention\\nDementia, changing of mental state or any mental illness which could hinder understanding or informed consent or fill out questionnaires;\\nHistory of allergy or hypersensitivity to any therapeutic ingredient;\\nCombined with other malignant tumors excepted pancreatic cancer within the first 5 years of randomization, excepted well-treated basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical resection, and ductal carcinoma in situ of the breast after radical resection;\\nPreviously received systemic therapy for advanced/metastatic pancreatic cancer;\\nSubjects who had previously been pathologically diagnosed with squamous cell carcinoma (no organ limitation) and received neoadjuvant/adjuvant therapy with taxa regimen.\\nPatients who had Grade 2 or above Peripheral neuropathy according to CTCAE Ver. 5.0.\\n\\n6. Abnormal results of physical examination and laboratory examination\\n\\nAbsolute neutrophil count (ANC) ≥ 1.5×109/L; Platelets (PLT) ≥ 80×109/L; Hemoglobin (Hb) ≥ 90g/L\\nAspartate aminotransferase (AST, or serum glutamic oxaloacetic transaminase, SGOT) and alanine aminotransferase (ALT, or serum glutamic pyruvate transaminase, SGPT) > 2.5 × ULN (institutional upper limit of normal), > 5 ×ULN (hepatic metastases occasion); Total bilirubin (TBIL)>1.5 × ULN;\\nCreatinine (CRE)> 1.5 × ULN\\nProthrombin time (PT) and international normalized ratio (INR) > 1.5 × ULN. Or activated partial thromboplastin time (aPTT) > 1.5 × ULN. Unless the subject had received anticoagulant treatment\\nSubjects had hepatitis b surface antigen (HBsAg)-positive and HBV-DNA titer in peripheral blood greater than or equal to 1000 copy number /L; If HBsAg is positive and the HBV-DNA of peripheral blood ≥ 1000 copy number/L, the subjects will be eligible for inclusion if the investigator considers that chronic hepatitis b is stable and does not increase the risk of subjects.\\n\\n4. Human immunodeficiency virus (HIV)- or hepatitis C virus (HCV) positive patients; 5. Patients who suffer from active infection requiring systemic treatment; 6. Patients need other concomitant anti-tumor drugs; 7. Participation in any trial drug treatment or another interventional clinical trial 30 days before screening period.\\n\\n8. Other conditions that the investigators considered are not suitable for the enrollment.\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02637596']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['February 2013']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Quality of Life After Radiofrequency Ablation of Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nhistologically proved locally advanced or metastatic pancreatic cancer. Patients with histologically proved resectable pancreatic cancer with low Karnofsky index.\\n\\ninformed consent\\n\\nExclusion Criteria:\\n\\ncystic tumor\\n\\nage under 18']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01994681']\n",
      "Phase: []\n",
      "Start Date: ['October 2013']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air']\n",
      "EligibilityCriteria: ['Pancreatic cancer Group\\n\\nInclusion Criteria:\\n\\nAge from 18 years old\\nPancreatic cancer positive biopsy\\nBefore any treatment\\nSigned Informed Patient Consent\\n\\nExclusion Criteria:\\n\\nAge under 18 years old\\nNeoadjovant treatment\\nPost surgery for Pancreatic cancer\\nA history of any other cancer type, except skin cancer that is not melanoma\\n\\nHealthy Group\\n\\nInclusion Criteria:\\n\\nHealthy patients\\nNo history of Pancreatic cancer\\nSigned Informed Patient Consent\\n\\nExclusion Criteria:\\n\\nHistory of Pancreatic cancer\\nPancreatic cancer background in the family\\nA history of any other cancer type, except skin cancer that is not melanoma']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01298011']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['May 2011']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Resectable Pancreatic Cancer']\n",
      "Brief Title: ['Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatient has histologically or cytologically confirmed potentially resectable adenocarcinoma of the pancreas. Patients with islet cell neoplasms are excluded.\\n\\nDefinition of potentially operable disease\\n\\nStaging by high-quality, pancreatic protocol, helical abdominal computed tomography required (Endoscopic ultrasound is not required).\\nNo extension to superior mesenteric artery (SMA) and hepatic artery.\\nClear fat plane between the SMA and celiac axis.\\nNo extension to celiac axis and hepatic artery.\\nPatent superior mesenteric vein and portal vein.\\nNo evidence of distant or extra-hepatic disease by CT scans.\\nPretreatment histological or cytological confirmation of an adenocarcinoma.\\nMale or non-pregnant and non-lactating female, and ≥ 18 years of age.\\nIf a female patient is of child-bearing potential, she must have a negative serum pregnancy test (β hCG) documented within 72 hours of the first administration of study drug.\\nIf sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator.\\nPatient must have received no prior chemotherapy or radiation for pancreatic cancer and no exposure to gemcitabine and/or Abraxane\\n\\nPatient has the following blood counts at baseline:\\n\\nANC ≥ 1.5 x 109/L (1500 /mm³);\\nPlatelets ≥ 100 x 109/L; (100,000/mm³);\\nHgb ≥ 10 g/dL.\\n\\nPatient has the following blood chemistry levels at baseline:\\n\\nAST (SGOT), ALT (SGPT) ≤ 2.5 x upper limit of normal (ULN);\\nAlkaline phosphatase (AP) ≤ 2.5 X ULN;\\nTotal bilirubin ≤1.5 mg/dl;\\nSerum creatinine ≤1.5mg/dl or calculated clearance ≥ 50 mL/min/1.73 m² for patients with serum creatinine levels >1.5 mg/dl.\\nPatient has acceptable coagulation status as indicated by a PT within normal limits (±15%) and PTT within normal limits (± 15%).\\nPatient has an ECOG performance status PS 0-1.\\nPatient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study-related activities.\\n\\nExclusion Criteria:\\n\\nPatient has borderline resectable disease\\nPatient uses therapeutic coumadin for a history of pulmonary emboli or DVT.\\nPatient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.\\nPatient has known infection with HIV, hepatitis B, or hepatitis C.\\nPatient has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.\\nPrior chemotherapy or radiation for pancreatic cancer. Prior exposure to gemcitabine and/or Abraxane.\\nPatient has a history of allergy or hypersensitivity to the study drugs.\\nPatient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug.\\nPatient is unwilling or unable to comply with study procedures.\\nPatient is enrolled in any other therapeutic clinical protocol or investigational trial.\\nPatient has metastatic disease on radiological staging.\\nPatients aged ≥ 80 are not excluded. As two events of fatal sepsis have been seen in this group in other studies, candidates in this age group should be thoroughly evaluated before enrollment in the study, to ensure they are fit to receive chemotherapy. In addition to meeting all of the baseline patient selection criteria, clinical judgment on their susceptibility to infection and expected stability of their performance status as to receive repeat weekly chemotherapy cycles, should be paid special attention to. Patients should not be enrolled in the study should there be any hesitation on any of these considerations. Baseline criteria for all patients enrolled on the study must be carefully evaluated and all criteria followed appropriately.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT06166147']\n",
      "Phase: []\n",
      "Start Date: ['December 22, 2023']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection']\n",
      "EligibilityCriteria: ['Cancer Arm\\n\\nInclusion Criteria:\\n\\n40-75 years old\\nClinically and/or pathologically diagnosed pancreatic cancer\\nNo prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.\\nAble to provide a written informed consent and willing to comply with all part of the protocol procedures.\\n\\nExclusion Criteria:\\n\\nPregnancy or lactating women\\nKnown prior or current diagnosis of other types of malignancies comorbidities\\nSevere acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.0 °C) within 14 days prior to blood draw\\nRecipients of organ transplant or prior bone marrow transplant or stem cell transplant\\nRecipients of blood transfusion within 30 days prior to study blood draw\\nRecipients of therapy in past 14 days prior to blood draw, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide\\nOther conditions that the investigators considered are not suitable for the enrollment\\n\\nBenign Disease Arm\\n\\nInclusion Criteria:\\n\\n40-75 years old\\nClinically and/or pathologically diagnosed pancreatic non-malignant disease (pancreatic intraepithelial neoplasia, pancreatic cyst and chronic pancreatitis)\\nNo prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.\\nAble to provide a written informed consent and willing to comply with all part of the protocol procedures\\n\\nExclusion Criteria:\\n\\nPregnancy or lactating women\\nKnown prior or current diagnosis of other types of malignancies comorbidities\\nSevere acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.0 °C) within 14 days prior to blood draw\\nRecipients of organ transplant or prior bone marrow transplant or stem cell transplant\\nRecipients of blood transfusion within 30 days prior to study blood draw\\nRecipients of therapy in past 14 days prior to blood draw, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide\\nOther conditions that the investigators considered are not suitable for the enrollment']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04276909']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['December 1, 2023']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Feasibility Study of LUM Imaging System for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nSubjects must have histological or cytological confirmation of pancreatic cancer on a biopsy prior to the operation with planned surgical resection. Subjects at any cancer stage will be enrolled.\\nAge of 18 years or older.\\nSubjects must be able and willing to follow study procedures and instructions.\\nSubjects must have received and signed an informed consent form.\\nSubjects must be otherwise healthy except for the diagnosis of cancer, as per the exclusion criteria listed below.\\nSubjects must have normal organ and marrow function as defined below:\\nLeukocytes > 3,000/mcL\\nAbsolute neutrophil count > 1,500/mcL\\nPlatelets > 100,000/mcL\\nAST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal\\nCreatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.\\nSubjects with ECOG performance status of 0 or 1.\\n\\nExclusion Criteria:\\n\\nSubjects who are pregnant or nursing at the time of diagnosis\\nSubjects who are sexually active and not willing/able to use medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015.\\nSubjects who have taken an investigational drug within 30 days of enrollment.\\nSubjects who have not recovered from adverse events due to other pharmaceutical or diagnostic agents.\\nSubjects with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 100 mm Hg; those subjects with known HTN should be under these values while under pharmaceutical therapy.\\nHistory of allergic reaction attributed to drugs containing polyethylene glycol (PEG).\\nHistory of allergic reaction to any oral or intravenous contrast agents.\\nUncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.\\nSubjects with QT interval > 470 ms.\\nHIV-positive individuals on combination antiretroviral therapy are ineligible.\\nAny subject for whom the investigator feels participation is not in the best interest of the subject.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03614910']\n",
      "Phase: []\n",
      "Start Date: ['May 15, 2018']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nage >18\\nlocally advanced unresectable pancreatic ductal adenocarcinoma as demonstrated by CT or MRI\\nmust have received standard chemotherapy and completed at least four cycles of treatment at least 5 weeks prior to therapy with Nanoknife\\nINR <1.5\\nable to tolerate laparotomy (medical/cardiac clearance as needed)\\nable to comply with protocol requirements\\nwomen of childbearing potential must have a negative serum pregnancy test and be practicing an effective form of birth control\\n\\nExclusion Criteria:\\n\\npatients with tumor >5cm after completion of chemotherapy\\npresence of metastatic disease\\npatients with a pacemaker or electrostimulator\\nestimated survival is less than 3 months\\npresence of a metallic stent (biliary or duodenal) which cannot be removed or exchanged for plastic\\nECOG performance status more than or equal to 2\\nepilepsy or other convulsive conditions\\ncannot tolerate general anesthesia\\npatients with atrial fibrillation who have an undetectable wave form on the ECG synchronization device\\npatients with inducible ischemia on cardiac stress test or uncontrolled angina\\nwhite blood cell count less than or equal to 2,000, absolute neutrophil count <1,000, platelets <50,000']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01989000']\n",
      "Phase: ['Not Applicable']\n",
      "Start Date: ['November 2013']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPatients with pancreatic tumors, with histological or cytological proof of adenocarcinoma or a high suspicion on CT imaging.\\nTumor size ≥ 1cm.\\nWHO-performance score 0-2.\\nScheduled for surgery or neo-adjuvant chemotherapy/radiation followed by surgery. For the reproducibility part of the study, patients who will not undergo surgery, may be included, too.\\nWritten informed consent.\\n\\nExclusion Criteria:\\n\\nAny psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol.\\nContra-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; or a non-MR compatible aneurysm clip in their brain; patients with severe claustrophobia.\\nRenal failure (GFR < 30 ml/min) hampering safe administration of Gadolinium containing MR contrast agent.\\nFor the reproducibility part of the protocol: surgery, radiation and/or chemotherapy foreseen within the timeframe needed for MR scanning.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04931381']\n",
      "Phase: ['Phase 3']\n",
      "Start Date: ['June 1, 2021']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Advanced Pancreatic Cancer']\n",
      "Brief Title: ['Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nAge≥18 years old and ≤80 years old.\\nHistologically or cytologically confirmed local advanced/metastatic pancreas adenocarcinoma.\\nEligible histologic variants include adenocarcinoma or variants to include mucinous adenocarcinoma or adenosquamous carcinoma.\\nPatient must have a tumor lesion that is amenable to a core needle biopsy.\\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\\nLife expectancy of greater than 90 days, as judged by the investigator.\\nRoutine blood test: absolute neutrophil count>1500/mm3, platelet>100000/mm3.\\nNormal liver function: serum total bilirubin≤2.0mg/dl, alanine aminotransferase (ALT) and aspertate aminotransferase (AST) <2.5 times of the upper limit of normal value.\\nNormal kidney function: serum creatinine<1.5 times of the upper limit of normal value or creatinine clearance rate>45ml/min.\\nThe pancreatic cancer organoid were cultured successfully.\\nNo severe comorbidities.\\n\\nExclusion Criteria:\\n\\nPatients with poor condition can not tolerate chemotherapy and targeted therapy.\\nImpaired organ functions: heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.\\nPatients diagnosed with other cancer within 5 years.\\nPatients who are pregnant or breastfeeding.\\nPatients enrolled in other clinical trials or incompliant of regular follow up.\\nPatients who did not provide an informed consent.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT06139042']\n",
      "Phase: []\n",
      "Start Date: ['November 1, 2023']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Liver Cancer', 'Biliary Tract Cancer', 'Pancreatic Cancer']\n",
      "Brief Title: ['Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers']\n",
      "EligibilityCriteria: ['Criteria:\\n\\nInclusion Criteria for Cancer Arm Participants:\\n\\nAge 40-75 years at the day of consenting to the study. Able to provide a written informed consent. Pathologically confirmed liver, biliary tract and pancreatic cancers. No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw.\\n\\nExclusion Criteria for Cancer Arm Participants:\\n\\nPregnancy or lactating women. Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant.\\n\\nRecipients of blood transfusion within 7 days prior to study blood draw. Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancers.\\n\\nWith other known malignant tumors or multiple primary tumors.\\n\\nInclusion Criteria for Benign Arm Participants:\\n\\nAge 40-75 years at the day of consenting to the study. Able to provide a written informed consent. Confirmed diagnosis of benign liver, biliary tract and pancreatic diseases. No prior radical treatment of the benign diseases prior to study blood draw.\\n\\nExclusion Criteria for Benign Arm Participants:\\n\\nPregnancy or lactating women. Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant.\\n\\nRecipients of blood transfusion within 7 days prior to study blood draw. Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancers.\\n\\nConfirmed diagnosis of malignancies or precancerous lesion. A history of malignant tumors.\\n\\nInclusion Criteria for Healthy Arm Participants:\\n\\nAble to provide a written informed consent.\\nAble to provide sufficient and qualified blood samples for study tests.\\nNo cancer related symptoms within 30 days prior to study screening.\\nCancer history with curative treatment completed over 3 years without recurrence prior to study enrollment.\\n\\nExclusion Criteria for Healthy Arm Participants:\\n\\nInsufficient qualified blood sample for study test.\\nDuring pregnancy or lactation.\\nRecipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.\\nRecipient of blood transfusion within 30 days prior to study blood draw.\\nRecipient of anti-infectious therapy within 14 days prior to study blood draw.\\nHave received or are undergoing curative cancer treatment within three years prior to study screening.\\nWith autoimmune or other diseases with severe comorbidities.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00424827']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['June 2006']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['A Trial of Chemo & Radiation Therapy for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHistological confirmation of pancreatic adenocarcinoma is required.\\nOnly patients with unresectable, non-metastatic tumors are eligible.\\nDocumentation of disease extent by endoscopic ultrasound and either laparotomy or laparoscopy must be performed within 42 days of registration.\\nAll patients will also be assessed by chest x-ray and abdominal-pelvic CT scan.\\nConfirmation of palliative surgical bypass at the time of laparotomy or whether a biliary stent was placed will be requested.\\n\\nDisease must be locoregional and not amenable to surgery based on one or more of the following criteria:\\n\\nsize of pancreatic tumor > 5 cm.\\nlymph nodes (bulky, > 2 cm, but within a radiation port)\\nvascular involvement or impingement of major vessels (superior mesenteric artery, superior mesenteric vein, portal vein, hepatic artery).\\ninvasion into the adjacent structures.\\nPatients with either measurable or evaluable disease are eligible.\\nPatients with evidence of peritoneal seeding by malignancy are not eligible for the study.\\nPatients with other evidence of metastatic disease are not eligible.\\nPatients with concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are ineligible.\\nPatients with any other malignancy within 5 years of study entry, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are ineligible.\\nPatients may not have had prior therapy for carcinoma of the pancreas, nor prior abdominal radiation therapy.\\nAge > 18 years.\\nCTC performance status < 2.\\nNo myocardial infarction in the past six months.\\nNo major surgery in the past two weeks.\\nNo uncontrolled serious medical or psychiatric illness.\\n\\nRequired Initial Laboratory Data:\\n\\nTotal bilirubin < 2.0 mg/dl\\nAST < 3x upper limits of normal.\\nSerum creatinine < 2.0 mg/dl\\nWBC > 3,000/mm3 (ANC>1500/mm3)\\nPlatelets > 100,000 mm3\\nCA 19-9\\n\\nRequired Diagnostic procedures:\\n\\nChest X-ray\\nAbdominal pelvic CT scan\\nEUS\\nStaging laparoscopy or staging laparotomy\\n\\nExclusion Criteria:\\n\\nEnrollment in this trial will be limited to patients for whom protocol therapy is safe and appropriate. Physicians should consider the risks and benefits of therapy together with all relevant medical and other considerations in deciding whether this protocol is appropriate for a particular patient. Specific considerations include:\\n\\nPsychiatric illness which would prevent the patient from giving informed consent.\\nSerious medical illness such as uncontrolled infection, severe cardiovascular disease including recent (< 6 months) myocardial infarction or uncontrolled congestive heart failure, or other serious illness which would limit anticipated survival to < 12 weeks.\\nProtocol treatment would pose significant risk to an unborn child. Pregnant women should not be enrolled, and women of child-bearing age should be strongly encouraged to practice effective birth control during and for three months after the trial.\\nInability to swallow medication. Patients should have adequate, unassisted oral intake.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03721744']\n",
      "Phase: ['Phase 3']\n",
      "Start Date: ['October 25, 2018']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHistologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.\\nMust have at least failed first line therapy\\nHas one or more metastatic tumors evaluable by CT scan with contrast (or MRI, if patient is allergic to CT contrast media) per RECIST 1.1\\n\\nExclusion Criteria:\\n\\nAnti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of chemotherapy within period of time equivalent to the usual cycle length of the regimen\\nPrior taxane therapy in the neoadjuvant or adjuvant setting with progression occurring within 6 months of completion of taxane therapy; or any taxane therapy in the locally advanced or metastatic setting.\\nPatient has experienced a decline in ECOG performance status between baseline visit and within 3 days prior to randomization']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00125021']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['October 2003']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer', 'Neoplasm Metastasis']\n",
      "Brief Title: ['Tarceva and Capecitabine for Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nMetastatic pancreatic carcinoma (excluding pancreatic endocrine tumors)\\nOnly patients with measurable disease\\nECOG performance status < or equal to 1\\nLife expectancy >12 weeks\\nSigned informed consent\\nFailed or intolerance to first-line therapy for metastatic disease with a gemcitabine-containing regimen. Patients may have received adjuvant therapy in addition to one prior regimen for metastatic disease.\\n>4 weeks must have elapsed from the completion of previous chemotherapy and patients must have recovered from any related toxicities\\n>4 weeks must have elapsed from the participation in any investigational drug study\\n\\nLaboratory values:\\n\\nANC > 1500/mm3;\\nHemoglobin > 9.0 gm/dl;\\nPlatelets > 100,000/mm3;\\nSGOT <2.5 X upper limit of normal; or <5 X upper limit of normal if evidence of liver metastases; Alkaline phosphatase < 2.5 X upper limit of normal; or < 5 X upper limit of normal if evidence of liver metastases; Total bilirubin < 1.5 X upper limit of normal; Creatinine clearance > 50 cc/min (by Cockroft - Gault or as determined from a 24-hour urine collection).\\n\\nExclusion Criteria:\\n\\nPrior therapy with capecitabine or epidermal growth factor receptor (EGFR) inhibitors\\nMore than one prior chemotherapy treatment regimen for metastatic disease\\nClinically apparent central nervous system (CNS) metastases or carcinomatous meningitis\\nClinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication or heart attack within the last 12 months).\\nMajor surgery within 4 weeks of the start of study treatment, without complete recovery.\\nEvidence of CNS metastases (unless CNS metastases have been stable for > 3 months) or history of uncontrolled seizures, central nervous system disorders\\nUncontrolled serious medical or psychiatric illness\\nWomen must not be pregnant or lactating\\nConcurrent radiation therapy\\nOther active malignancy\\nInability to swallow tablets\\nPatients lacking physical integrity of the upper gastrointestinal tract or who have malabsorption syndrome\\nPrior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02506803']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['July 2015']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPathologically proven invasive pancreatic ductal carcinoma\\n\\nCases that meet the definition of borderline resectable pancreatic cancer 1) or 2)\\n\\nDefinition of a borderline resectable pancreatic cancer is filledin NCCN guideline version 1.2014 pancreatic adenocarcinoma\\nPatients indicated distal pancreatectomy with en bloc celiac axis resection\\nPS (ECOG) 0-1\\n≧20 years old and < 80 years old\\nFirst line treatment\\nThe following criteria must be satisfied in laboratory tests within 14 days of registration White blood cell count ≦12,000/mm3 Neutrophil count ≧1,500/mm3 Platelet count ≧100,000mm3 Total bilirubin <2.0mg/dL Serum Creatinine ≦upper limits of normal(ULN) AST, ALT≦2.5×ULN Albumin≧3.0g/dL Hemoglobin≧9.0g/dL\\nWritten informed consent to participate in this study\\n\\nExclusion Criteria:\\n\\nSevere drug hypersensitivity\\nMultiple primary cancers within 5 years\\nSevere infection\\nWith grade2 or more severe peripheral neuropathy\\nWith intestinal paralysys, ileus\\nInterstitial pneumonia or pulmonary\\nWith uncontrollable pleural effusion or ascites\\nReceiving atazanavir sulfate\\nWith uncontrollable diabetes\\nWith uncontrollable heart failure, angina, hypertension, arrhythmia\\nWith severe psychological symptoms\\nWith watery diarrhea\\nPregnant or lactating women, or women with known or suspected pregnancy\\nInappropriate patients for entry on this study in the judgment of the investigator']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT04101929']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['October 1, 2019']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Metastatic Pancreatic Cancer']\n",
      "Brief Title: ['Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nInformed consent and willing to complete the study according to the protocol\\nECOG performance scale ≤ 2;\\nDiagnosed as pancreatic adenocarcinoma by histology and cytology;\\nTreatment of patients with advanced metastatic pancreatic cancer who have failed with AG (albumin and gemcitabine) regimen\\n\\nBaseline blood routine and biochemical indexes meet the following criteria:\\n\\nBlood routine examination criteria must be met: (no blood transfusion within 14 days)\\n\\nHB≥90g/L；\\nANC≥1.5×109/L；\\nPLT≥80×109/L\\n\\nBiochemical tests are subject to the following criteria:\\n\\nBIL <1.25xULN ；\\nALT and AST<2.5ULN；\\nSerum creatinine. Less than 1 times the upper limit of normal value, Endogenous creatinine clearance>50ml/min ( Cockcroft-Gault formula).\\nThe advanced pancreatic cancer pathology, with measurable lesions (spiral CT scan is more than 10 mm, according to the standard of RECIST 1.1);\\nLife expectancy ≥ 12 weeks;\\nDoctors believe that treatment can bring benefits to patients.\\n\\nExclusion Criteria:\\n\\nunwilling or unable to comply with the study protocol;\\nOther or malignant tumors in the past or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ;\\nAllergy to apatinib, S-1 raw materials and/or their excipients;\\nReceived VEGFR inhibitors, such as sorafenib, chougny for treatment;\\nHave high blood pressure and antihypertensive drug treatment can not drop to normal range(systolic pressure >140 mmHg, diastolic blood pressure 90>mmHg);\\nSuffering from coronary artery disease above grade I, grade I arrhythmia (including corrected QT interval prolongation male > 450 ms, women > 470 MS) and grade I heart insufficiency; urine protein positive patients.\\nRenal insufficiency, patients with previous kidney disease, urine protein positive (urinary protein detection 2+ or above, or 24-hour urine protein quantitation > 1.0g);\\nHas a variety of factors influencing oral drugs (such as unable to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.)\\nPregnant or lactating women;\\nCoagulant function abnormality (INR>1.5、APTT>1.5 ULN) with bleeding tendency; Those with bleeding tendency (such as active ulcerative lesions in the stomach, fecal occult blood (++), vaginal and/or hematemesis within 3 months, hemoptysis) or lesions close to the large vessel site;\\nPatients with a deficiency of dihydropyrimidine dehydrogenase are known;\\nEvidence of any severe or uncontrolled systemic disease (eg, unstable or decompensated breathing, heart, liver or kidney disease, HIV infection, high blood pressure, severe arrhythmia, diabetes, massive active bleeding);\\nPatients with a history of psychotropic substance abuse who are unable to quit or have a mental disorder;\\nAccording to the investigator's judgment, there are other serious patients who are at risk to the patient's safety or affect the patient's accompanying disease.\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00529113']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['September 30, 2007']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Neoplasms', 'Pancreatic Cancer']\n",
      "Brief Title: ['Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPhase I patients should have treatment naïve pancreatic cancer; however , Phase I patients who have had 1 prior regimen consisting of adjuvant chemo-radiation or adjuvant gemcitabine - as defined within the NCCN guidelines may be enrolled. Phase II patients must have metastatic disease (Stage IV only).\\nKarnofsky performance status of >70%\\nAdequate liver function. (total bilirubin ≤ 1.5 mg/dL and AST(SGOT) and ALT(SGPT) of < 2.5 ULN ( ≤ 5 ULN for Phase II patients with liver metastases), Serum Creatinine < 1.5 ULN\\nAdequate bone marrow function as documented by the following laboratory test results within 14 days of starting therapy. platelets ≥100,000/mm3, absolute neutrophil count (ANC) ≥1500/mm3, hemoglobin ≥9.0 g/dL, white blood cell (WBC) count ≥3000 /mm3\\nPractice effective contraception during the entire study period.\\nLife expectancy of more than 3 months.\\nAble and willing to sign the informed consent form.\\nWilling and able to self-administer orally and document all doses of RTA 402 ingested.\\n\\nExclusion Criteria:\\n\\nPrior treatment for current malignancy outside of the adjuvant setting for Phase I\\nInability to swallow tablets or capsules\\nActive brain metastases or primary central nervous system (CNS) malignancies. (Patients with a previously treated brain metastasis may be included.)\\nActive second malignancy\\nTen percent or greater weight loss over the 6 weeks before study entry.\\nPregnant or breast feeding\\nClinically significant illnesses which could compromise participation in the study, including, but not limited to: Uncontrolled diabetes; Active or uncontrolled infection; Acute or chronic liver disease; Confirmed diagnosis of Human immunodeficiency virus (HIV) infection; Uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.\\nPsychiatric illness that would limit compliance with study requirements.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT02148549']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['April 2014']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Patients With Borderline Resectable Pancreatic Cancer']\n",
      "Brief Title: ['Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nPathologically proven invasive pancreatic ductal carcinoma\\n\\nCases that meet the definition of borderline resectable pancreatic cancer 1) or 2)\\n\\nDefinition of a borderline resectable pancreatic cancer is filledin NCCN guideline version 1.2014 pancreatic adenocarcinoma\\nPatients indicated distal pancreatectomy with en bloc celiac axis resection\\nPS (ECOG) 0-1\\n≧20 years old and < 75 years old\\nFirst line treatment\\nThe following criteria must be satisfied in laboratory tests within 14 days of registration White blood cell count ≦12,000/mm3 Neutrophil count ≧1,500/mm3 Platelet count ≧100,000mm3 Total bilirubin <2.0mg/dL Serum Creatinine ≦upper limits of normal(ULN) AST, ALT≦2.5×ULN Albumin≧3.0g/dL Hemoglobin≧9.0g/dL\\nWritten informed consent to participate in this study\\n\\nExclusion Criteria:\\n\\nSevere drug hypersensitivity\\nMultiple primary cancers within 5 years\\nSevere infection\\nWith grade2 or more severe peripheral neuropathy\\nWith intestinal paralysys, ileus\\nInterstitial pneumonia or pulmonary\\nWith uncontrollable pleural effusion or ascites\\nReceiving atazanavir sulfate\\nWith uncontrollable diabetes\\nWith uncontrollable heart failure, angina, hypertension, arrhythmia\\nWith severe psychological symptoms\\nWith watery diarrhea\\nPregnant or lactating women, or women with known or suspected pregnancy\\nInappropriate patients for entry on this study in the judgment of the investigator\\nWith UGT1A1*28 and/or UGT1A1*6 polymorphisms']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT05848154']\n",
      "Phase: []\n",
      "Start Date: ['June 1, 2023']\n",
      "Study Type: ['Observational']\n",
      "Condition: ['Patients With Non-metastatic Pancreatic Cancer', 'Evaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic Adenocarcinoma']\n",
      "Brief Title: ['Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nNewly diagnosed patients with non-metastatic pancreatic cancer;\\nThe pathological features were identified as pancreatic ductal carcinoma;\\nPatients with clinical risk factors including significantly elevated CA19-9 levels at diagnosis, large primary tumor volume, large regional lymph node diameter, significant weight loss, and extreme pain;\\nPatients accept neoadjuvant chemotherapy voluntarily with the regimen of modified FOLFIRINOX, and disease evaluation should be conducted every two courses, surgery should be performed without delay if resection criteria have been met, and at least two courses of chemotherapy should be completed;\\nAge ≥18 years old;\\nNo other tumor treatment within 4 weeks prior to enrollment;\\nComplete clinical data, including basic information, pathological information, treatment information;\\nThe subjects voluntarily join the study and sign the informed consent with good compliance, and cooperate with the acquisition of tissue samples and regular blood samples.\\n\\nExclusion Criteria:\\n\\nAny other systemic antitumor therapy priorly;\\nConcomitant malignancies under treatment;\\nPatients with a history of allergy to relevant chemotherapy agents;\\nFailure to comply with the requirements of the visit plan;\\nPatients who may be absent from the visit period for 2 weeks or more during the treatment period;\\nThe researchers determine that the subjects have other factors that could have caused the study to be discontinued.']\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT03585062']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['November 20, 2017']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer', 'Neoadjuvant Chemotherapy']\n",
      "Brief Title: ['Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nConfirmed invasive ductal adenocarcinoma of pancreas by histology\\nEvaluated as CT4N0M0 pancreatic cancer patients by Image testing\\nAdults age from 18-80 years old\\nNo history of pancreatic resection or pancreatic cancer\\nECOG score 0-1; can be orally administered\\nNo distant metastasis or malignant ascites\\nRelatively good liver、 kidney、heart、hematology function. Baseline blood routine and biochemical indexes of the subjects meet the following criteria: hemoglobin ≥90g/L;absolute neutrophil count(ANC)≥3.5×109/L；Platelet≥100×109/L;prothrombin time ≤1.8;partial thromboplastin time ≤1.8; ALT≤102U/L、AST≤95U/L; ALP≤2.5 times the upper limits of normal; Serum total bilirubin≤2.5 g/dL(total bilirubin ≤1.5 times the upper limit of normal (ULN)；Serum creatinine≤2.0 mg/dL； creatinine clearance rate >50 ml/min\\nSign the Informed consent -\\n\\nExclusion Criteria:\\n\\nWoman in pregnant or lactation period\\nWoman of childbearing age who was positive at baseline pregnancy test or did not have pregnancy tests.Menopausal women must have menopause for at least 12 months before they think they are free of pregnancy.\\nMen and women who had sexual life (Fertility possibility) were reluctant to have contraception during the study period.\\nPatients with the history of other malignant diseases in the past 5 years, except for cured skin cancer and cervical carcinoma in situ.\\nPatients of uncontrolled epilepsy, central nervous system diseases or history of mental disorders, should be judged by the researchers whether their clinical severity hinder the signature of the informed consent or influenced patients'compliance with oral medications\\nClinically serious (i.e. activity) heart disease, such as symptomatic coronary heart disease , New York Heart Association (NYHA) class II or more serious congestive heart failure or serious arrhythmia which need drug intervention, or have a history of MI within the last 12 months.\\nPatients with upper gastrointestinal obstruction or Abnormal physiological function or Malabsorption syndrome, which may affect the absorption of S-1.\\nOrgan transplant patients who need immunosuppressive therapy\\nPatients with Serious uncontrolled repeated infection or other serious uncontrolled Concomitant disease.\\nPatient that is lack of dihydropyrimidine dehydrogenase (DPD)\\nAllergic to any of the drug ingredients in this study\\nparticipate in other clinical trials within 4 weeks before randomization -\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT01296763']\n",
      "Phase: ['Phase 1']\n",
      "Start Date: ['January 2011']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer']\n",
      "EligibilityCriteria: [\"Inclusion Criteria:\\n\\nProvision of fully informed consent prior to any study specific procedures.\\nHistologic or cytologic confirmation of exocrine pancreatic adenocarcinoma.\\nLocally advanced, inoperable (due to venous or arterial encasement ≥ 180° of the vessel), and/or metastatic disease by imaging (CT, MRI, or EUS). Acquisition of tissue rather than cytology is encouraged if the patient gives informed consent.\\nMeasurable disease according to RECIST 1.1 criteria\\nPrior neoadjuvant or adjuvant therapy is acceptable, as long as no more than one drug of the ICM regimen was used.\\nNo prior chemotherapy for advanced pancreatic cancer with Olaparib is permitted. Gemzar, Tarceva, and 5-FU or Xeloda, Oxaliplatin Taxotere, and FOLFIRINOX are permitted.\\nThree weeks since last surgery or chemotherapy mentioned in #5 above or investigational therapies. Four weeks since radiation.\\nNo prior PARP inhibitors of any type\\nECOG status < 3\\nLife expectancy > 3 months\\nPatients must have normal organ and bone marrow function\\nAge >=18.\\nPatient is willing and able to comply with the protocol for the duration of the study including treatment, scheduled visits, and examinations.\\n\\nEvidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1\\n\\nFor inclusion in genetic research, patients must fulfill the following criterion:\\n\\nProvision of informed consent for genetic research. If a patient declines to participate in the genetic research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.\\n\\nExclusion Criteria:\\n\\nPatients with second primary cancer, except: adequately treated non-melanoma skin cancer or curatively treated in-situ solid tumors with no evidence of disease for ≥ 5 years.\\nPatients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), less than 3 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment.\\nFor patients who have locally advanced pancreatic cancer only, if they have received therapeutic doses of radiation therapy to their pancreatic bed (~50 Gy) for treatment of their locally advanced pancreatic cancer\\nPatients having already had prior chemotherapy for more than 12 months for their advanced pancreatic cancer (not including adjuvant/neoadjuvant)\\nPatients receiving the following classes of inhibitors of CYP3A4 (see Section for guidelines and wash out periods).\\nCurrent use of azole antifungals, macrolide antibiotics, or protease inhibitors\\nUnresolved toxicities (>CTCAE 4.0 grade 2) caused by previous cancer therapy.\\nPatients with known brain metastases. A scan to confirm the absence of brain metastases is not required unless the initial examination reveals CNS signs of disease.\\nMajor surgery less than 3 weeks prior to starting study treatment and patients must have recovered from any effects of any major surgery.\\nPatients considered a poor medical risk due to serious, uncontrolled medical disorders, non-malignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.\\nPatients unable to swallow oral medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\\nBreast feeding and/or pregnant women.\\nImmunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).\\nPatients with known active hepatic disease (i.e., Hepatitis B or C). Patients with a known hypersensitivity to Olaparib or any of the excipients of the product or history of severe allergic reactions to platinums or chemotherapy.\\nGrade 2 neuropathy at entry from any etiology, including diabetes (in view of Cisplatin).\\nPrior episodes of recurrent deep vein thrombosis or Trousseau's Syndrome unless the patient is successfully anticoagulated. If a patient has had a history of clotting or is suspected to have Trousseau's syndrome and is not anticoagulated, a D-Dimer level will be checked. If it is > 3 x ULN, patients will be expected to be anticoagulated with low molecular weight heparinoids (i.e. Lovonox).\"]\n",
      "\n",
      "----------------------------------------\n",
      "\n",
      "NCT ID: ['NCT00521404']\n",
      "Phase: ['Phase 2']\n",
      "Start Date: ['August 15, 2007']\n",
      "Study Type: ['Interventional']\n",
      "Condition: ['Pancreatic Cancer']\n",
      "Brief Title: ['Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer']\n",
      "EligibilityCriteria: ['Inclusion Criteria:\\n\\nHistologically or cytologically confirmed resectable or metastatic pancreatic cancer; not previously treated with chemotherapy; measurable disease; 18 years of age or older\\n\\nExclusion Criteria:\\n\\nAnticipation of need for major surgery or radiation therapy during the study\\nHeart Disease exclusions: myocardial infarction or unstable angina within the past 6 months; severe or unstable angina pectoris within the past 6 months; coronary or peripheral artery bypass graft within the past 6 mo., etc.\\nClinically significant active infection or history of HIV\\nPartial or complete bowel obstruction\\nPoorly controlled psychiatric illness']\n",
      "\n",
      "----------------------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "def search_clinical_trials(search_term, max_results=10):\n",
    "    base_url = \"https://ClinicalTrials.gov/api/query/study_fields\"\n",
    "    params = {\n",
    "        \"expr\": search_term,\n",
    "        \"min_rnk\": 1,\n",
    "        \"max_rnk\": max_results,\n",
    "        \"fields\": \"NCTId,Phase,StartDate,StudyType,Condition,BriefTitle,EligibilityCriteria\",\n",
    "        \"fmt\": \"json\",\n",
    "    }\n",
    "\n",
    "    response = requests.get(base_url,params=params)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        data = response.json()\n",
    "        studies = data.get(\"StudyFieldsResponse\", {}).get(\"StudyFields\", [])\n",
    "        \n",
    "        for study in studies:\n",
    "            print(f\"NCT ID: {study.get('NCTId')}\")\n",
    "            print(f\"Phase: {study.get('Phase')}\")\n",
    "            print(f\"Start Date: {study.get('StartDate')}\")\n",
    "            print(f\"Study Type: {study.get('StudyType')}\")\n",
    "            print(f\"Condition: {study.get('Condition')}\")\n",
    "            print(f\"Brief Title: {study.get('BriefTitle')}\")\n",
    "            print(f\"EligibilityCriteria: {study.get('EligibilityCriteria')}\")\n",
    "            print(\"\\n\" + \"-\"*40 + \"\\n\")\n",
    "\n",
    "    else:\n",
    "        print(f\"Error: Unable to fetch data. Status code: {response.status_code}\")\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    search_term = input(\"Enter a search term for clinical trials: \")\n",
    "    max_results = int(input(\"Enter the maximum number of results to retrieve: \"))\n",
    "    \n",
    "    search_clinical_trials(search_term, max_results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Defaulting to user installation because normal site-packages is not writeable\n",
      "Collecting owlready2\n",
      "  Using cached owlready2-0.45.tar.gz (27.3 MB)\n",
      "  Installing build dependencies ... \u001b[?25lerror\n",
      "  \u001b[1;31merror\u001b[0m: \u001b[1msubprocess-exited-with-error\u001b[0m\n",
      "  \n",
      "  \u001b[31m×\u001b[0m \u001b[32mpip subprocess to install build dependencies\u001b[0m did not run successfully.\n",
      "  \u001b[31m│\u001b[0m exit code: \u001b[1;36m1\u001b[0m\n",
      "  \u001b[31m╰─>\u001b[0m \u001b[31m[13 lines of output]\u001b[0m\n",
      "  \u001b[31m   \u001b[0m Collecting setuptools\n",
      "  \u001b[31m   \u001b[0m   Using cached setuptools-68.0.0-py3-none-any.whl (804 kB)\n",
      "  \u001b[31m   \u001b[0m Collecting wheel\n",
      "  \u001b[31m   \u001b[0m   Using cached wheel-0.42.0-py3-none-any.whl (65 kB)\n",
      "  \u001b[31m   \u001b[0m Collecting Cython\n",
      "  \u001b[31m   \u001b[0m   Using cached Cython-3.0.7-py2.py3-none-any.whl (1.2 MB)\n",
      "  \u001b[31m   \u001b[0m Installing collected packages: wheel, setuptools, Cython\n",
      "  \u001b[31m   \u001b[0m ERROR: Could not install packages due to an OSError: [Errno 13] Permission denied: '/Library/Python/3.7/site-packages/wheel/__init__.py'\n",
      "  \u001b[31m   \u001b[0m Consider using the `--user` option or check the permissions.\n",
      "  \u001b[31m   \u001b[0m \n",
      "  \u001b[31m   \u001b[0m \n",
      "  \u001b[31m   \u001b[0m [notice] A new release of pip is available: 23.0.1 -> 23.3.2\n",
      "  \u001b[31m   \u001b[0m [notice] To update, run: /Library/Developer/CommandLineTools/usr/bin/python3 -m pip install --upgrade pip\n",
      "  \u001b[31m   \u001b[0m \u001b[31m[end of output]\u001b[0m\n",
      "  \n",
      "  \u001b[1;35mnote\u001b[0m: This error originates from a subprocess, and is likely not a problem with pip.\n",
      "\u001b[?25h\u001b[1;31merror\u001b[0m: \u001b[1msubprocess-exited-with-error\u001b[0m\n",
      "\n",
      "\u001b[31m×\u001b[0m \u001b[32mpip subprocess to install build dependencies\u001b[0m did not run successfully.\n",
      "\u001b[31m│\u001b[0m exit code: \u001b[1;36m1\u001b[0m\n",
      "\u001b[31m╰─>\u001b[0m See above for output.\n",
      "\n",
      "\u001b[1;35mnote\u001b[0m: This error originates from a subprocess, and is likely not a problem with pip.\n",
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m23.0.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m23.3.2\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49m/Library/Developer/CommandLineTools/usr/bin/python3 -m pip install --upgrade pip\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "!pip install owlready2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "* Owlready2 * Warning: optimized Cython parser module 'owlready2_optimized' is not available, defaulting to slower Python implementation\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Importing UMLS from umls-2019AA-metathesaurus.zip with Python version 3.11.5 and Owlready version 2-0.45...\n"
     ]
    },
    {
     "ename": "FileNotFoundError",
     "evalue": "[Errno 2] No such file or directory: 'umls-2019AA-metathesaurus.zip'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mFileNotFoundError\u001b[0m                         Traceback (most recent call last)",
      "\u001b[1;32m/Users/mgalusza/PhD/srl/srl/read_ct_gov.ipynb Cell 3\u001b[0m line \u001b[0;36m5\n\u001b[1;32m      <a href='vscode-notebook-cell:/Users/mgalusza/PhD/srl/srl/read_ct_gov.ipynb#W1sZmlsZQ%3D%3D?line=2'>3</a>\u001b[0m \u001b[39mfrom\u001b[39;00m \u001b[39mowlready2\u001b[39;00m\u001b[39m.\u001b[39;00m\u001b[39mpymedtermino2\u001b[39;00m\u001b[39m.\u001b[39;00m\u001b[39mumls\u001b[39;00m \u001b[39mimport\u001b[39;00m \u001b[39m*\u001b[39m\n\u001b[1;32m      <a href='vscode-notebook-cell:/Users/mgalusza/PhD/srl/srl/read_ct_gov.ipynb#W1sZmlsZQ%3D%3D?line=3'>4</a>\u001b[0m default_world\u001b[39m.\u001b[39mset_backend(filename \u001b[39m=\u001b[39m \u001b[39m\"\u001b[39m\u001b[39mpym.sqlite3\u001b[39m\u001b[39m\"\u001b[39m)\n\u001b[0;32m----> <a href='vscode-notebook-cell:/Users/mgalusza/PhD/srl/srl/read_ct_gov.ipynb#W1sZmlsZQ%3D%3D?line=4'>5</a>\u001b[0m import_umls(\u001b[39m\"\u001b[39;49m\u001b[39mumls-2019AA-metathesaurus.zip\u001b[39;49m\u001b[39m\"\u001b[39;49m, terminologies \u001b[39m=\u001b[39;49m [\u001b[39m\"\u001b[39;49m\u001b[39mICD10\u001b[39;49m\u001b[39m\"\u001b[39;49m, \u001b[39m\"\u001b[39;49m\u001b[39mSNOMEDCT_US\u001b[39;49m\u001b[39m\"\u001b[39;49m, \u001b[39m\"\u001b[39;49m\u001b[39mCUI\u001b[39;49m\u001b[39m\"\u001b[39;49m])\n\u001b[1;32m      <a href='vscode-notebook-cell:/Users/mgalusza/PhD/srl/srl/read_ct_gov.ipynb#W1sZmlsZQ%3D%3D?line=5'>6</a>\u001b[0m default_world\u001b[39m.\u001b[39msave()\n",
      "File \u001b[0;32m/Library/Frameworks/Python.framework/Versions/3.11/lib/python3.11/site-packages/owlready2/pymedtermino2/umls.py:692\u001b[0m, in \u001b[0;36mimport_umls\u001b[0;34m(umls_zip_filename, terminologies, langs, fts_index, extract_groups, extract_attributes, extract_relations, extract_definitions, remove_suppressed)\u001b[0m\n\u001b[1;32m    688\u001b[0m         default_world\u001b[39m.\u001b[39msave()\n\u001b[1;32m    689\u001b[0m         previous_parser \u001b[39m=\u001b[39m table_name\n\u001b[0;32m--> 692\u001b[0m \u001b[39mwith\u001b[39;00m zipfile\u001b[39m.\u001b[39;49mZipFile(umls_zip_filename, \u001b[39m\"\u001b[39;49m\u001b[39mr\u001b[39;49m\u001b[39m\"\u001b[39;49m) \u001b[39mas\u001b[39;00m umls_zip:\n\u001b[1;32m    693\u001b[0m   filenames \u001b[39m=\u001b[39m \u001b[39msorted\u001b[39m(umls_zip\u001b[39m.\u001b[39mnamelist())\n\u001b[1;32m    695\u001b[0m   \u001b[39m#for filename in filenames:\u001b[39;00m\n\u001b[1;32m    696\u001b[0m   \u001b[39m#  if filename.endwiths(\"/META/\") or filename.endwiths(\"/META\"):\u001b[39;00m\n\u001b[1;32m    697\u001b[0m   \u001b[39m#    full_umls = False\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    700\u001b[0m \n\u001b[1;32m    701\u001b[0m   \u001b[39m#if full_umls:\u001b[39;00m\n",
      "File \u001b[0;32m/Library/Frameworks/Python.framework/Versions/3.11/lib/python3.11/zipfile.py:1284\u001b[0m, in \u001b[0;36mZipFile.__init__\u001b[0;34m(self, file, mode, compression, allowZip64, compresslevel, strict_timestamps, metadata_encoding)\u001b[0m\n\u001b[1;32m   1282\u001b[0m \u001b[39mwhile\u001b[39;00m \u001b[39mTrue\u001b[39;00m:\n\u001b[1;32m   1283\u001b[0m     \u001b[39mtry\u001b[39;00m:\n\u001b[0;32m-> 1284\u001b[0m         \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mfp \u001b[39m=\u001b[39m io\u001b[39m.\u001b[39;49mopen(file, filemode)\n\u001b[1;32m   1285\u001b[0m     \u001b[39mexcept\u001b[39;00m \u001b[39mOSError\u001b[39;00m:\n\u001b[1;32m   1286\u001b[0m         \u001b[39mif\u001b[39;00m filemode \u001b[39min\u001b[39;00m modeDict:\n",
      "\u001b[0;31mFileNotFoundError\u001b[0m: [Errno 2] No such file or directory: 'umls-2019AA-metathesaurus.zip'"
     ]
    }
   ],
   "source": [
    "from owlready2 import *\n",
    "from owlready2.pymedtermino2 import *\n",
    "from owlready2.pymedtermino2.umls import *\n",
    "default_world.set_backend(filename = \"pym.sqlite3\")\n",
    "import_umls(\"umls-2019AA-metathesaurus.zip\", terminologies = [\"ICD10\", \"SNOMEDCT_US\", \"CUI\"])\n",
    "default_world.save()\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
